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Abstract 
 
 
Skeletal muscle atrophy is a devastating condition and a characteristic of many disease 
states and a strong predictor of morbidity and mortality. Skeletal muscle is a highly 
plastic tissue and changes in mass, fibre size, fibre composition, strength and elasticity 
are common. Investigating therapeutic targets and understanding the molecular and 
physiological contributions to the regulation of skeletal muscle is a prerequisite for 
improving clinical outcomes. G-CSF, a readily available and safe pharmacological 
agent, has recently become of interest in the treatment of skeletal muscle post trauma. In 
skeletal muscle, G-CSF improves muscle strength following injury in rodents. The 
enhancement of muscle function is preceded by a significant increase in satellite cell 
proliferation, decreased apoptosis, increased regeneration, and higher muscle protein 
content. In other rodent models, G-CSF increases muscle repair following a local 
cardiotixin injection. The signalling pathways known to propagate the effects of G-CSF 
in haematopoietic cells, neural tissue and cardiac myocytes are of vital importance in 
skeletal muscle. Therefore, G-CSF may be a promising therapeutic compound to 
ameliorate skeletal muscle atrophy. However, the molecular mechanisms by which G-
CSF regulates skeletal muscle have not clearly been established.  
 
This first study showed that the G-CSFR was expressed in C2C12 and human primary 
myoblasts and myotubes and in mature skeletal muscle. Using a rodent model of 
Duchennne muscular dystrophy (DMD), the mdx mouse, G-CSF mRNA and protein 
were down-regulated in the tibialis anterior (TA) and diaphragm muscle. However, the 
G-CSFR was down-regulated at the protein level in muscle tissue of the TA and 
diaphragm despite an elevated expression of G-CSFR mRNA.  
 
Using C2C12 myoblasts this thesis aimed to determine if G-CSF treatment increased 
myoblast proliferation or differentiation. G-CSF treatment did not stimulate C2C12 
myoblast proliferation. Furthermore, using gene expression markers of differentiation, 
myosin heavy chains (I, IIa, IIb and IIx) and the myogenic regulatory factors MyoD and 
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myogenin, G-CSF treatment did not affect differentiation. However G-CSF treatment 
(100 ng/ml) did increase G-CSFR mRNA at day 3 and day 4 during differentiation. 
Since the G-CSFR was identified on myoblasts it was important to determine if G-CSF 
treatment activated intracellular signalling activity. Here it was shown that Akt, and 
Erk1/2 are responsive to media change effects, and G-CSF did not increase 
phosphorylation of these proteins above the vehicle control.  
 
In chapter 4 G-CSF treatments did not influence protein synthesis. However, G-CSF 
treatment did influence protein synthesis under Dexamethasone (DEX)-induced 
catabolic conditions. DEX induces a reduction in basal protein synthesis and G-CSF 
treatment, at 4 and 40 ng/ml, partially attenuated this effect. In contrast, at 100 ng/ml G-
CSF had a catabolic effect further exacerbating the DEX-induced reduction in protein 
synthesis. G-CSF treatment did not influence protein degradation under normal or 
DEX-induced catabolic conditions.  Similar to the results obtained from chapter 3, G-
CSF did not increase phosphorylation of Akt, STAT3 or Erk1/2 in C2C12 myotubes.  
 
In chapter 5 it was shown for the first time that LPS treatment increased G-CSF mRNA 
expression and G-CSF release from C2C12 myotubes. As expected LPS treatment 
induced an inflammatory profile increasing mRNA expression of TNFα, IL-6 and MCP-
1 and release of IL-6 and MCP-1 from C2C12 myotubes. The addition of G-CSF did not 
influence MCP-1 or TNFα however further increased IL-6 above that of LPS alone. In 
response to eccentric damaging-exercise in humans, G-CSF was elevated in circulation 
after 2 hours. This study showed that the increase in circulating G-CSF did not 
correspond to an increased G-CSF in the skeletal muscle tissue. This study also showed 
that the G-CSFR was not altered. 
 
These findings expand our current knowledge of G-CSF function in skeletal muscle. 
Previous research has found that G-CSF increases C2C12 proliferation and activation of 
intracellular signalling pathways such as Akt, STAT3 and Erk1/2. This thesis 
contradicts these findings showing that G-CSF treatment does not increase C2C12 
myoblast proliferation or activation of these proteins. Furthermore, this thesis shows 
that the G-CSFR is expressed on myotubes in vitro and mature skeletal muscle and that 
G-CSF treatment modulates myotube protein synthesis under catabolic conditions. G-
CSF modulated the inflammatory response by increasing IL-6 following LPS 
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stimulation of C2C12 myotubes. Since G-CSF was not elevated using an in vivo human 
model of muscle damage, eccentric exercise, the response may differ in vivo, or may 
differ as to the type of inflammatory stimulus. This thesis does however provide 
supporting evidence to warrant an in vivo rodent study using G-CSF as a therapeutic 
agent in mdx mice and for the treatment of sepsis induced atrophy.   
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CHAPTER ONE 
 
Review of the Literature 
 
1.1 Skeletal Muscle  
Skeletal muscle is the most abundant tissue in the human body. It represents nearly half 
the total body mass and 50-75% of total body protein [1]. The skeletal muscle system is 
a highly developed organ system, connecting to the skeleton to produce controlled 
movement via the contraction and relaxation of muscle groups. Skeletal muscle is 
extremely important for everyday locomotion and fine motor control while facilitating 
vital bodily processes such as breathing and thermal regulation. Thus, skeletal muscle is 
fundamental to our survival. 
 
Skeletal muscle is a highly plastic tissue and changes in mass, fibre size, fibre 
composition, strength and elasticity are common. Myofibres are incapable of mitotic 
division [2] and rely on a population of myogenic stem cells, known as satellite cells, to 
regulate growth and regeneration [3]. In addition, the regulation of protein turnover can 
result in increases in muscle fibre size and muscle mass, known as hypertrophy, or a 
decrease in muscle fibre size and muscle mass, known as atrophy [4, 5]. The most 
potent and obvious beneficial stimuli for skeletal muscle adaptation is exercise. For 
example, resistance exercise is a known stimulus for the activation of myogenesis and 
muscle protein synthesis, resulting in gains in muscle strength, muscle mass and fibre 
size [6]. In contrast, protein degradation and a reduction in myogenesis results in a loss 
in muscle mass and muscle strength and is usually seen as a consequence of disuse, 
aging and/or disease [7].  
 
1.1.1 Myogenesis  
The formation of skeletal muscle, known as myogenesis, occurs due to the activation of 
satellite cells during postnatal development, and during times of postnatal growth and 
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regeneration [3, 8]. Satellite cells are quiescent skeletal muscle specific cells which lie 
beneath the basal lamina in adult muscle until they are stimulated to enter the cell cycle 
[9]. When satellite cells enter the cell cycle they proliferate and are termed myoblasts 
(Figure 1-01) [8]. A differentiation stimulus causes cell cycle arrest, where myoblasts 
proliferation ceases, and myoblasts commit to one of two fates; a return to quiescence to 
replenish the satellite cell pool or a dedication to myogenesis [3, 8, 10]. The satellite 
cell committed to myogenesis, fuses with an existing myofibre and donates its nuclei. 
Increased mechanical load, injury or disease is a major stimulus for the activation of 
satellite cells [3, 8, 11-14]. This is a highly complex and tightly regulated process 
whereby the myogenic potential of satellite cells relies on several genes and 
transcription factors. 
 
Activation and fate of the satellite cells is under the control of the Paired box (Pax) 
genes, and a family of transcription factors known as myogenic regulatory factors 
(MRF) during myogenesis [3]. Quiescent satellite cells show little gene activity, 
however express Pax7 [15] which is confined only to muscle derived stem cells [16]. 
Pax7 is believed to be important in the activation of satellite cells and fundamental to 
maintaining the population of quiescent satellite cells [16-18].  In response to a 
differentiation stimuli, Pax7 functions upstream of the MRF myogenic differentiation-1 
(MyoD) [19, 20] causing its upregulation [15]. Thus, satellite cell activation is 
characterized by the rapid onset of MyoD expression (Figure 1-01) [21]. Activated, 
satellite cells proliferate, and cells which down-regulate Pax7 and up-regulate MyoD 
committ to myogenesis, while a loss of MyoD expression and an up-regulation of Pax7 
see satellite cells return to quiescence (Figure 1-01). Expressed later in myogenesis is 
the MRF myogenin. Myogenin-/- mice suffer from perinatal lethality due to the lack of 
mature secondary skeletal muscle fibres [22], demonstrating myogenin’s important role 
in skeletal muscle development. Myogenin marks the commitment of myoblasts to 
differentiation [21].  
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Figure 1-01 Satellite cell activation through to myotube formation. Satellite cells, when 
activated, increase MyoD and enter the cell cycle to become proliferating myoblasts. When 
myoblasts reach the site of muscle formation, myoblasts committed to myogenic differentiation 
increases expression of Myogenin, line up and fuse into multinucleated myofibres. Myoblasts not 
committed to myogenic differentiation decrease MyoD expression, increase Pax7 expression and 
return to quiescence to replenish the satellite cell pool [3]. 
 
There are a number of other cells that show myogenic potential. Bone marrow derived 
stem cells (BMDSC) expressing green fluorescent protein (GFP) generate GFP 
expressing myofibres following injury in mice [23, 24]. Following transplantation, GFP 
expressing mononuclear cells are observed beneath the basal lamina in injured, non-
injured and dystrophic mice, suggesting BMDSC potentially replenish the satellite cell 
pool [25, 26]. Interestingly, age related muscle loss is associated with a reduction in 
satellite cell activity [27, 28] and a reduction in circulating bone-marrow derived cells 
[29, 30]. A side population of muscle derived stem cells (MDSC), show pluripotency 
and are capable of forming any cell of haematopoietic lineage [31-33] and actively 
participate in the formation of skeletal muscle in dystrophic mice [34]. Thus, it appears 
within the muscle environment various cells commit to a myogenic pathway.  
 
1.1.2 Regulation of Protein Turnover in Skeletal Muscle 
The continual and fine balance between protein synthesis and protein degradation 
results in the maintenance of skeletal muscle mass [4, 5]. When the balance between 
these processes shifts, muscle growth, known as hypertrophy or muscle wasting, known 
as atrophy can occur [4, 10, 35].  
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The most potent and obvious stimuli for muscle hypertrophy is resistance exercise 
(REX). Acute REX leads to an increase in protein synthesis 2-4 hours post exercise [36] 
which may last up to 48 hours [37]. REX training leads to increased muscle strength, 
muscle mass and fibre size [10, 38]. Skeletal muscle is also highly responsive to a 
dietary intake of nutrient rich food [39, 40]. Amino acid ingestion increases protein 
synthesis and inhibits protein degradation resulting in a positive net protein turnover 
[41]. Lastly, growth factors and growth agents such as testosterone increases protein 
synthesis and lead to hypertrophy [42-44].  
 
In contrast, increased protein degradation, often caused by inactivity, malnutrition, 
aging, disease and trauma result in muscle atrophy [4, 5, 39, 45-50]. Muscle atrophy is a 
debilitating condition and a characteristic of neuromuscular disorders such as Duchenne 
muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS) [51], and chronic 
diseases such as cancer, heart disease, chronic obstructive pulmonary disease (COPD), 
sepsis, AIDS and limb immobilization [7]. Muscle atrophy during these conditions is 
seen as one of the most potent stimuli restricting treatment and recovery [7, 52, 53]. 
Thus, muscle atrophy is a strong predictor of morbidity and mortality associated with 
these diseases, which are among the leading causes of death worldwide [54, 55]. 
Therefore developing therapeutic strategies aimed at improving skeletal muscle health is 
fundamental to our well-being. 
 
1.1.3 Current Therapies For Skeletal Muscle  
Exercise is regarded as the most effective global treatment to promote healing and 
combat muscle atrophy. Prolonged exercise training prevents muscle loss in the elderly 
and is an effective mechanism for improving muscle function, muscle mass and strength 
during rehabilitation [49, 56]. Amino acid supplementation activates key signalling 
pathways involved in protein synthesis [57] and when used in conjunction with 
resistance exercise, individuals can see massive gains in muscle strength and mass [1] 
or limit the disease severity associated with atrophy [58-61]. While exercise and 
nutritional interventions are effective tools for improving muscle function they are not 
always possible. The severity of muscle atrophy observed in diseases such as DMD and 
ALS, in the aging population and following injury can render certain individuals 
incapacitated and unable to perform daily tasks [52]. Therefore exercise and nutritional 
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interventions are best used as a preventative therapy. The development of therapeutic 
drugs to alleviate severe muscle atrophy and restore quality of life remains a necessity.  
 
Current drugs for regulating skeletal muscle growth and regeneration include anabolic 
steroids, growth factors and growth promoters [62, 63]. Testosterone, an anabolic 
steroid which stimulates androgen and oestrogen receptors to increase protein synthesis 
[64], is most beneficial when used in conjunction with exercise [65, 66]. Insulin like 
growth factor-1 (IGF-1), an anabolic agent stimulates its own receptor to promote 
cellular proliferation and protein synthesis, resulting in growth [67, 68]. Transgenic 
overexpression of IGF-1 leads to muscle hypertrophy in rodents [69], however intra 
peritoneal (i.p) administration of a recombinant IGF-1 does not [69]. Different isoforms 
of the IGF-1 receptor are expressed by a wide range of tissues, and the altered response 
from different delivery methods of recombinant IGF-1 leads to speculation that 
recombinant IGF-1 may cause severe side effects [70]. Clenbuterol, a high dose β-
adrenoceptor agonist can increase protein synthesis and decrease protein degradation 
causing hypertrophic response in skeletal muscle [52]. Since the emergence of long 
term side effects of clenbuterol use, and the presence of β-adrenoceptor expressed in 
non-skeletal muscle, there is an air of caution surrounding its systemic use [71]. 
Therefore understanding the molecular mechanisms behind skeletal muscle plasticity is 
vital for the development of therapeutic drugs. 
 
1.1.4 The Inflammatory Response and its Role in Muscle Plasticity 
Following skeletal muscle damage, the integrity of the muscle and structural 
components are disrupted which is followed by the self-digestion of cellular 
components known as autolysis [72]. Within several hours neutrophils invade the 
skeletal muscle and are the most abundant immune cell at the injury site [13, 73-77]. 
Their primary role is to remove damaged tissue by phagocytosis with numbers declining 
after about 24 hours [12, 78, 79]. The decline in neutrophils coincides with the 
infiltration of monocytes. Monocytes within the muscle differentiate to macrophages 
[11] and remain for up to 14 days [13, 73, 80-83], switching the environment to anti-
inflammatory [11]. Lastly, the activation of satellite cells repairs the damaged tissue 
[79, 84].  
 
Inflammation has a controversial role as being both beneficial and detrimental to muscle 
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regeneration [11, 72, 85, 86]. The inflammatory response is important for the 
hypertrophic responses of damaging exercise [87-89]. Following damage, macrophage 
infiltration coincides with the induction of satellite cell regulatory factors such as MyoD 
[12] suggesting that satellite cells may interact with macrophages providing a crucial 
link between inflammation and repair [90]. Inhibition of the immune cell response by 
bone marrow depletion reduces the regenerative capacity of skeletal muscle in rodents 
[11, 91-93]. Via the release of cytokines [79], neutrophils and macrophages are linked 
to the activation of satellite cells and intracellular signalling cascades controlling protein 
turnover. However, they also release reactive oxygen species (ROS), causing oxidative 
stress and secondary muscle damage to the surrounding tissue [79]. ROS are chemically 
active molecules such as superoxide, hydrogen peroxide and hypochlorous acid that 
non-specifically damage all components of the cell by oxidative stress [94]. ROS are 
released mainly from neutrophils, in a process known as respiratory burst [95]. 
Sustained ROS production leads to damage of healthy tissue surrounding the injury site, 
known as secondary muscle damage [96]. However, ROS are known to activate 
signalling pathways involved in myogenesis and protein turnover, leading to myotube 
hypertrophy in C2C12 cells via IGF-1 [97].  
 
Chronic inflammation, characterised by an increase in circulating leukocytes [98] and a 
2-4 fold increases in systemic levels of pro-inflammatory cytokines, is associated with 
skeletal muscle atrophy [98-101]. Certainly, cancer cachexia is associated with chronic 
low grade inflammation and an up-regulation of protein degradation [102, 103]. Rodent 
models of DMD have constantly high levels of muscle resident neutrophils, chronically 
elevated cytokine levels and undergo continual degeneration and regeneration of muscle 
tissue [104]. Thus, the duration, the severity of inflammation and the cytokine profile 
are suggested to be important factors in the muscular responses to inflammation. 
  
1.1.5 The Role of Cytokines in Skeletal Muscle  
There are two classes of cytokines; pro-inflammatory or anti-inflammatory, which as 
the names suggest, depends on their ability to initiate or prevent inflammation [105-
107]. A subset of cytokines classified by their ability to remove leukocytes from the 
circulation, are known as chemokines [108]. The main stimuli for the production of 
cytokines include tissue damage, bacterial products and viral infection [109]. 
Chemokines, while activated by these stimuli, are also activated by early pro-
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inflammatory cytokines [110]. 
 
In the initial stages following skeletal muscle damage, released cytokines are 
predominantly pro-inflammatory [107, 111]. Cytokines and chemokines bind to 
matching surface receptors to induce intracellular signalling pathways to initiate a wide 
range of cellular functions [112]. These act as chemo attractants for infiltrating immune 
cells and activate intramuscular signalling cascades involved in regeneration, including 
an activation of satellite cells and protein turnover [12, 91, 113-115]. Therefore, 
understanding the how cytokines influence muscle remains an important for developing 
effective therapeutic agents for skeletal muscle. 
 
The local release of the pro-inflammatory cytokines such Tumour Necrosis Factor alpha 
(TNFα) and interleukin (IL)-1 induce the expression of endothelial-leukocyte adhesion 
molecules (E-selectin) and chemokines such as monocyte chemoattractant protein 1 
(MCP-1) [116]. E-selectin loosely binds leukocytes to the endothelial wall [117] and as 
the inflammatory process continues the release of chemokines strongly binds leukocytes 
to the endothelial wall and facilitates their passage into the damages tissue. This process 
is necessary for muscle repair as MCP-1 deficient mice have impaired regeneration 
following ischemia-reperfusion injury [92]. However, the release of ROS is often 
initiated by pro-inflammatory cytokines [118], thus causing further damage.  
 
Recently, muscle itself has been identified as a source of cytokine production. Myocytes 
release IL-6, transforming growth factor beta (TGF-β), granulocyte-macrophage colony 
stimulating factor (GM-CSF), IL-1α, IL-1β TNFα, IL-8 and MCP-1 when stimulated 
with a variety of pro-inflammatory cytokines in vitro [108, 119]. Cultured human 
myotubes release IL-8, GM-CSF, granulocyte-colony stimulating factor (G-CSF), 
MCP-1, and IL-6 following stretch induced damage in vitro [116]. These findings 
suggest skeletal muscle itself may drive muscle repair and muscle plasticity by releasing 
“myokines” [106, 120, 121].  
 
There is conflicting evidence for the role of cytokines in skeletal muscle. TNFα can 
protects myoblasts from apoptosis [122], but induces apoptosis in myotubes [123]. 
TNFα is linked to muscle wasting in cancer and sepsis [59, 124], and TNFα treatment of 
C2C12 myotubes decreases protein synthesis [125] and results in a net protein loss [122]. 
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In direct contrast, TNFα increases muscle protein synthesis in C2C12 myotubes and rat 
primary myotubes [126, 127]. Significant differences between treatment time points and 
TNFα concentrations make it hard to elicit a clear role for TNFα. This is clearly evident 
in L6 myotubes where treatment with high and low dose TNFα is catabolic, however a 
mid-range dose is anabolic [128]. IL-6 is produced locally by muscle fibres and by 
satellite cells, and is considered a true myokine [129]. The multiple functions of IL-6 in 
skeletal muscle, may depend on the mechanisms, disease or source of increased IL-6 
[130]. For example, IL-6 is considered an anti-inflammatory cytokine by supressing IL-
1 and TNFα [131] and precedes the appearance of anti-inflammatory cytokines IL-1 
receptor agonist (IL-1ra) and IL-10 [132]. Its role in skeletal muscle hypertrophy is well 
documents where genetic loss of IL-6 results in a reduced satellite cell proliferation 
induced hypertrophy, in rodent muscle [129]. However, high doses or long-term 
exposure to IL-6, is linked to skeletal muscle catabolism and muscle atrophy [130, 133, 
134]. The interaction of IL-6 with other molecules is postulated to contribute to muscle 
atrophy during disease states such as chronic kidney disease. In chronic kidney disease 
an increased angiotensin II (Ang II) is hypothesised to increase IL-6 [130]. This is 
demonstrated in rodents where Ang II increases IL-6 which is accompanied with muscle 
atrophy [135]. The atrophy is completely attenuated in IL-6 deficient mice. 
 
Recently the cytokine granulocyte-colony stimulating factor (G-CSF), a commercially 
available and ‘safe’ pharmacological agent emerged as a potential therapeutic drug for 
skeletal muscle repair. G-CSF increases muscle mass following crush injury, increases 
muscle function in rodent models of ALS and increases regeneration following a local 
cytotoxic injection (CTX) [136-138]. G-CSF is currently used as a therapeutic drug in a 
variety of cancer treatments [139-141], for bone marrow and stem cell transplants [142, 
143], for stem cell donations, blood disorders [144-147] and in conjunction with HIV 
treatments [148]. Therefore, it may present itself as an easily accessible therapeutic 
agent to combat muscle wasting. However, the molecular mechanisms of G-CSF action 
in skeletal muscle are widely unknown.  
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1.2 Granulocyte-Colony Stimulating Factor  
1.2.1 The G-CSF Ligand 
G-CSF is a member of a family of secreted glycoproteins that regulate the survival, 
proliferation, differentiation and function of haematopoietic cells [149, 150]. G-CSF is a 
cytokine and hormone [151], first recognised for the formation of neutrophil colonies 
from bone marrow cultures [152, 153]. It is widely known for its ability to stimulate the 
mobilisation of haematopoietic stem cell from the bone marrow [152, 154], while 
simultaneously stimulating cell survival, proliferation, and differentiation of 
granulocytic precursors and activation of neutrophils [155, 156]. 
 
The G-CSF gene exists as a single copy located on chromosome 17 in humans and 
chromosome 11 in mice, and is approximately 2500 base pairs in length [157-159]. The 
coding sequence is highly conserved between the human and mouse genome with 69 % 
homology [160]. The promoter region upstream of the transcription initiation site has a 
300bp sequence identical in human and mouse [160]. G-CSF was originally cloned 
from two separate cell lines. The tumour cell line 5637 [161] which codes for a 204 
amino acid precursor protein and the squamous cell carcinoma cell line CHU-2 [162] 
which coded for two different mRNAs producing two precursor proteins of 204 and 207 
amino acids in length. The N-terminus 30 amino acid domain contains a hydrophilic 
secretary signal which is cleaved upon secretion, producing peptides of 174 and 177 
amino acids in length [161, 162]. Subsequent studies showed the smaller protein was 
more potent at stimulating proliferation of progenitor cells [163] and the significance of 
the two mRNA sequences in CHU-2 cells remains unclear.   
 
G-CSF is a glycoprotein with the threonine residue being O-glycosylated in the human 
form [164]. This glycosylation appears to stabilise the protein and protect it from 
aggregation at low pH, but does not influence receptor binding and potency [165]. It is 
not clearly understood how G-CSF is synthesised, although, it appears G-CSF can be 
produced and secreted by most cells [151, 166]. Murine and human G-CSF have been 
successfully synthesised by recombinant DNA technology producing a non-
glycosylated polypeptide [156]. The non-glycosylated recombinant protein, produced in 
E.coli, retains high receptor affinity and biological function [167].  
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1.2.2 Clinical Applications of G-CSF  
The ability for G-CSF to increase neutrophil production and maturation as well as 
mobilise bone marrow stem cells strengthens the immune system [168]. As such, the 
drug Neupogen® (filgrastim) (AMGEN®), a recombinant form of G-CSF, was 
introduced in phase I clinical trials for patients receiving chemotherapy in the mid 
1980’s [169]. Recombinant G-CSF can be administered subcutaneously or 
intravenously with maximal serum concentrations around 40-50 ng/ml being reached 
after 2-8 hours [170]. At low doses, G-CSF mobilises peripheral blood progenitor cells 
in blood banking procedures for granulocyte collection [171, 172]. G-CSF is also used 
in conjunction with cancer treatment [139-141], for bone marrow or stem cell 
transplants [142, 143], blood disorders such as severe chronic neutropenia (SCN) or 
leukaemia [144-147] and in conjunction with HIV treatments [148]. Potential side-
effects associated with G-CSF treatment include bone pain, headache, fatigue, nausea, 
anxiety, chest pain, insomnia, night sweats, skin rashes, anorexia, dizziness, weight 
gain, local reactions at the injection site, and vomiting [150]. However, these side 
effects are considered minimal, with over-the-counter analgesics considered successful 
management, but only required following high doses of G-CSF administration [173].  
 
In contrast to its role in the blood, G-CSF is known to mobilise endothelial progenitor 
cells [174], mobilise dendritic cells [175], modulate the inflammatory response in septic 
patients [176-178] and play a role in liver repair in rats [179]. It is neuro-protective in 
vitro and in rodents [180-182], and has emerged as a potential therapeutic agent for 
cardiac muscle following damage [183-191]. Thus, contrary to original research, 
biological activity of G-CSF is not limited to myeloid cell lineages and the effects of G-
CSF on non-myeloid tissue need to be elucidated. The identification of the G-CSF 
receptor (G-CSFR) on tissues outside the haematopoietic system has been a catalyst for 
such research.   
 
1.2.3 The G-CSF Receptor  
The G-CSFR was discovered as a membrane protein expressed in myeloid leukaemia 
cells or neutrophilic granulocytes [192, 193]. It was first cloned in 1990 by Fukunaga et 
al. [159]. It is a type I transmembrane protein which belongs to the cytokine receptor 
superfamily predominantly expressed in cells of the haematopoietic system [151, 158, 
166]. Other receptors in this family include the gp130 signal-transducing subunit (IL-6 
Page | 11  
 
transducer), the erythropoietin (EPO) receptor and the growth hormone receptor [194-
197]. The G-CSFR human protein is an 813 amino acids polypeptide with a single 
transmembrane domain and a calculated molecular weight (Mr) of 90,814 [159]. Due to 
multiple glycosylation sites during post translation modification, its molecular weight 
has been reported between 85 – 150 kDa [198]. The homology between the human and 
mouse G-CSFR genome is 62.5 %, and there is cross reactivity between human and 
mouse (i.e. human G-CSF is active in murine cells and vice versa) [151, 157, 159]. 
Unlike many cytokine receptors, G-CSFR does not cross react with ligands of other 
receptors [197].  
 
The G-CSFR has a large extracellular domain that includes an immunoglobulin domain 
(Ig), the Cytokine Receptor Homology (CRH) domain and three fibronectin domains 
[199]. A 200 amino acid sequence in the CRH domain consists of four conserved 
cysteine residues, and a 5 amino acid Trp-Ser-X-Trp-Ser motif (WSXWS motif); a 
characteristic of the class I cytokine receptor superfamily [197]. The WSXWS motif 
provides a recognition site for the dimerization of two or more receptors by disulphide 
linkage [200]. This is crucial for signal transduction and receptor stability. Proximal to 
the transmembrane domain, the intracellular domain contains two conserved regions of 
the haematopoietic receptor family; Box 1 and Box 2, and a tyrosine residue (Y704) 
necessary for the induction of mitosis [201]. The distal domain contains three tyrosine 
residues (Y729, Y744, and Y764) (Figure 1-02). These tyrosine residues provide 
docking sites for intracellular protein kinases important for differentiation of cells 
expressing the G-CSFR [201-203].  
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Figure 1-02 Schematic representation of the G-CSFR protein. The external domain is composed 
of an immunoglobulin domain (Ig), the Cytokine Receptor Homology domain (CRH) that contains 
the WSXWS motif (solid black bar) and conserved cysteine residues. The cytoplasmic domain of 
the receptor contains Box 1 and Box 2 and four tyrosine residues (Y704, Y729, Y744, and Y764) 
[157, 204].  
 
In neutrophils, only a few of the lowly expressed receptors need to be occupied by G-
CSF to elicit a maximal biological response [155, 156]. At maturity, the expression of 
the G-CSFR is highest in neutrophils, but in recent years G-CSFRs have been identified 
outside the haematopoietic system (reviewed in [149]). Immunohistochemical staining 
of the rat embryo identified receptors in the cardiac ventricle, intestines, kidneys, blood 
vessels as well as, muscle precursor cells and retinal muscle tissue [205], suggesting G-
CSF has a ubiquitous and critical role during development. Furthermore, the G-CSFR 
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has been identified on cardiac myocytes [206].  
 
1.2.4 G-CSF/G-CSFR in Disease 
Mutations in the G-CSFR and alterations in G-CSF/G-CSFR expression are seen in 
multiple diseases. Approximately 20 % of SCN patients present with nonsense 
mutations in the C-terminus of the G-CSFR gene [207, 208] and lead to truncated 
receptors. Overexpression of these receptors in myeloid cells increases the proliferative 
response; however these myeloid cells lack an apparent differentiation stimulus in 
response to G-CSF [207]. SCN patients with point mutations and truncated G-CSFRs 
show a high tendency of developing acute myeloid leukaemia (AML) [207, 209]. In 
AML patients, a mutation in the transmembrane domain has been identified [210]. 
Overexpressing these mutated receptors increases proliferation of BAF/3 cells, an 
immortalised G-CSFR expressing murine bone marrow-derived pro-B-cell line, in the 
absence of G-CSF [211]. This mutation has parallel mutations in the GM-CSF receptor 
which leads to tumourigenicity [212]. Further mutations observed in AML patients lead 
to hyper-proliferative effects of the haematopoietic system [213].  A further 10 % of 
SCN patients who do not respond to G-CSF treatment present with mutations in the 
extra cellular domain of the G-CSFR [214]. These mutations cause frame shifts and 
again truncated receptors.  Heterodimerisation of truncated receptors and wild-type 
receptors supresses the G-CSF response in myeloid cells [214].  
 
Increased G-CSF and/or increased G-CSFR expression is associated with tumour 
growth. Over 90 % of ovarian cancers show expression of G-CSF and the G-CSFR 
[215, 216], however ovarian tissue normally does not express the G-CSFR. Bladder 
cancers express the G-CSFR during early formation [217-219], while epithelial cancers 
(squamous cell carcinoma) have elevated G-CSFR expression [220]. Thus, G-CSF 
potentially leads to enhanced proliferation and tumour growth via a paracrine/autocrine 
loop in these tissues. Increased levels of G-CSF are observed in serum and synovial 
fluid of patients with rheumatoid arthritis [221], while the G-CSFR is up-regulated 
following cerebral ischemia in rodents [222]. G-CSF and the G-CSFR is significantly 
elevated in the cerebrospinal fluid of ALS patients [181] and in the SOD1tg mouse, a 
rodent model of ALS, both G-CSF and G-CSFR mRNA expression is increased in 
neural tissue [223]. During the preparation of this thesis, protein expression of the G-
CSFR was identified in C2C12 myoblasts [138]. It remains unknown if G-CSF/G-CSFR 
Page | 14  
 
is modulated in diseased skeletal muscle. 
 
1.2.5 G-CSF as a Therapeutic Agent for Non- haematopoeitic Tissue 
In neural tissue, G-CSF has shown therapeutic benefits which was initiated by the 
observation that G-CSF could cross the blood-brain barrier in rats [222, 224, 225]. Rat 
cortical neural cells are protected against apoptotic death in vitro following G-CSF 
treatment [222]. G-CSF attenuates apoptotic death and improves the functional outcome 
in experimental models of spinal cord injury [180, 226]. And in a neuromuscular model 
of ALS, mice have improved motor function and life expectancy following G-CSF 
treatment [223]. Despite these improvements, the effects of G-CSF on skeletal muscle 
have not been investigated. 
 
Prompted by the identification of the G-CSFR on cardiac and neural tissue and the 
promising animal and in vitro studies [205, 206], G-CSF has made its way into clinical 
trials assessing its therapeutic benefits following myocardial infarction [190], ischemic 
stroke [227, 228], and is well on its way to clinical trials for Alzheimer’s disease [229, 
230]. In cardiac tissue, G-CSF stimulates cardiac myocyte proliferation both in vitro 
and in vivo in rodents, and improves cardiac function following an experimental 
myocardial infarct [206]. In 2005, G-CSF was progressed to clinical trials in patients 
following acute myocardial infarction with numerous trials completed so far (Reviewed 
in [190]). While early studies show significant improvements in left ventricular end-
diastolic volume and ejection volume following myocardial infarct [231, 232], others do 
not [233, 234]. Meta-analysis is inconclusive to elicit a clear answer as to the benefits of 
G-CSF following cardiac damage [235]. In 2010 stage IIa clinical trials proved G-CSF 
was safe at high doses for stroke victims [236] after small scale studies saw improved 
neurological functioning [227]. Improved memory in rodent models of Alzheimer’s 
disease [237] should see G-CSF progressed to clinical trials.   
 
Rodent studies indicate G-CSF is a beneficial therapeutic agent for skeletal muscle. It 
improves skeletal muscle functional outcomes post trauma [136, 137]. Significant 
increases in muscular strength seven and 14 days following crush injury is observed in 
rodents administered G-CSF during recovery [136]. Increases in cell proliferation, a 
moderate decrease in cell apoptosis, increased numbers of regenerating fibres, and 
increased satellite cell activation were observed in these mice. G-CSF+/+ and G-CSFR-/- 
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bone marrow, transplanted into wild-type and G-CSFR whole body knockout mice, has shown 
that bone marrow does not contribute to muscle regeneration [138], suggesting a direct effect of 
G-CSF on muscle. Furthermore, higher muscle protein content is observed in G-CSF 
treated mice following crush injury [136], ALS mice have improved motor function and 
have 55 % larger muscle fibres when treated with G-CSF [223], while and G-CSFR-/- 
mice are significantly smaller than their wild-type littermates [138], However, it is 
currently unknown if G-CSF directly regulates myogenesis or protein turnover in 
skeletal muscle cells. 
 
1.2.6 Intracellular Signalling Pathways of G-CSF 
Acute Transforming Rerovirus Thymona (Akt) 
The G-CSFR interacts with the Src-family of kinases known to activate Akt signalling 
upon ligation [238-240]. Two Src-family members, Lyn and Hck stimulate activate of 
phosphatidylinositol-3-kinase (PI3K) [238, 239] which in turn phosphorylates and 
activates Akt (Figure 1-03) [47, 68]. There are three isoforms of Akt named Akt1, Akt2, 
and Akt3. Akt1 null mice show severe muscle atrophy [241], Akt2 null mice have a 
milder growth deficiency but display a diabetic phenotype [242], while Akt3 null mice 
have smaller brains [243]. Thus, Akt1 is a key signalling protein in the cellular 
adaptations in skeletal muscle, and will here on be referred to as Akt [244-249]. 
Expression of a constitutively active Akt in mouse skeletal muscle increases myofibre 
hypertrophy and muscle mass [246, 247].  In contrast, inhibition of Akt leads to muscle 
atrophy [250, 251]. Homozygous dominant negative Akt1 mice have a significantly 
reduced body mass, a reduced life span and show growth retardation during 
development [250].  
 
Downstream of Akt, signalling targets have multifaceted functions (Figure 1-03) [244, 
246, 248, 249, 252]. Akt promotes cell cycle progression by phosphorylation of the 
downstream targets cyclinD, p21 and p27 [253]. cyclinD forms a complex with cyclin 
dependant kinases (Cdk) to drive transition from G1/S phase of the cell cycle [254], 
while p21 and p27 when phosphorylated by Akt remove their inhibition on Cdks [255]. 
In regulating protein synthesis, Akt phosphorylation of  mammalian target or rapamycin 
(mTOR) initiates protein synthesis through activation of S6 ribosomal protein and 
subsequent inhibition of eukaryotic initiation factor 4E binding protein 1 (4E-BP1) 
[256]. Secondly, glycogen synthase kinase-3β (GSK-3β), a ubiquitously expressed 
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protein kinase inhibits eukaryotic initiation factor 2B (eIF2B) and subsequently protein 
translation. Akt phosphorylation removes this inhibition by phosphorylating  GSK-3β 
[257-261]. The Forkhead box O (Foxo) transcriptional factors are sequestered to the 
cytoplasm by phosphorylated Akt, thus reducing protein breakdown [262] via a 
reduction in muscle specific atrophy genes, Atrogin-1 and Muscle RING-Finger 
protein-1 (MuRF1).  
 
 
 
Figure 1-03 Akt signalling.  Akt increases protein synthesis via phosphorylation inhibition of the 
GSK-3β pathway and phosphorylation activation of the mTOR pathway. Akt inhibits atrophy gene 
transcription by phosphorylation inhibition of Foxo transcription factors while regulating 
proliferation via p21, p27 and CyclinD.  
 
Signal Transducers and Activation of Transcription (STAT) 
G-CSF causes phosphorylation of cytoplasmic Janus Tyrosine Kinases (JAK; JAK1, 
JAK2 and Tyk2) [204]. There are four JAK members known in mammalian cells; the 
widely expressed JAK1, JAK2 and tyrosine kinase (TYK) 2, and JAK3 which is mainly 
found in haematopoietic cells [263]. Activated JAKs subsequently phosphorylate STAT 
family of transcription factors [264] that homo- or hetero- dimerise and translocate to 
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the nucleus where they bind DNA and activate the transcription of responsive genes 
(Figure 1-04) [263-265]. 
 
  
Figure 1-04 JAK/STAT signalling.  Cytokine/receptor binding cause the four cysteine residues 
within the cytokine receptor homology domain to provide disulphide linkage necessary for 
homodimerisation. Activation of Janus Tyrosine Kinase (JAK) causes phosphorylation and homo -
dimerisation of Signal transducers and activators of transcription (STAT) proteins. STAT proteins 
translocate to the nucleus where they activate transcription of target genes [266].  
 
Seven STAT members exist; STAT1-4, 5a, 5b and 6. Of the seven, STAT3 whole body 
knockout mice die during embryonic development [267]. STAT3 was the first member 
to be implicated in C2C12 myoblast proliferation [268, 269] and in rodent skeletal 
muscle in vivo [270]. STAT3 signalling via JAK1 prevents premature differentiation of 
C2C12 myoblasts [271], while STAT3 signalling via JAK2 positively regulates C2C12 
differentiation [272]. In mdx mice, a rodent model of muscular dystrophy, characterised 
by continual degeneration/regeneration, STAT3 is 6-fold higher than the littermate 
controls [273]. Following a single bout of resistance exercise, a rapid phosphorylation 
and nuclear translocation of STAT3 is evident in human skeletal muscle [274].  
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Extracellular signal-regulated Kinase 1/2 (Erk1/2) 
Erk1/2 are mitogen-activated protein kinases (MAPK) that respond to extracellular 
stimuli (mitogens, osmotic stress, exercise and pro-inflammatory cytokines) to regulate 
cellular functions such as gene expression, proliferation, differentiation, and cell 
survival/apoptosis [275-278].  Erk1/2 are activated by G-CSF via a region on the 
membrane-proximal cytoplasmic domain of the G-CSFR correlating to a JAK binding 
domain at both Y704 and Y764 [279]. Ligation induces Grb2 and Shc phosphorylation 
which mediates the activation of Erk1/2 downstream of Ras (Figure 1-05). Erk1/2 
translocates to the nucleus and activates a wide range of transcription factors and 
phosphorylates the protein kinase p90 ribosomal S6 kinase (p90RSK) [280].  p90RSK 
initiates protein synthesis via S6 ribosomal protein or translocates to the nucleus to 
phosphorylate transcription factors [280].  
 
Figure 1-05 Erk1/2 signalling.   The MAPK/Erk signalling cascade is activated by a wide variety 
of receptors involved in growth and differentiation. The central pathway of MAPK composed of a 
MAPKKK (Raf), a MAPKK (MEK1/2) and MAPK (Erk1/2)). Erk can regulate targets in the 
cytosol (p90RSK) and can translocate to the nucleus to activate transcription factors regulating 
gene expression. 
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Erk1/2 is implicated in skeletal muscle growth and development. Inhibition of the 
Erk1/2 pathway prevents proliferation and blocks G1 to S phase transition in a mouse 
myoblast (MM14) cell line [281]. Muscular contractions are a powerful stimulus for the 
activation of Erk1/2 [282-284], with increased phosphorylation in rodent skeletal 
muscle following mechanical ex vivo concentric, isometric and eccentric contractions 
[285]. Erk1/2 is phosphorylated in an intensity-dependent manner following cycling 
[286]. Inflammatory stimuli also activate Erk1/2. For example, IL-1β releases 
prostaglandins in astrocytes via Erk1/2 [287], while LPS stimulates inducible nitric 
oxide and cyclooxygenase-2 (COX-2) expression via Erk1/2 in macrophages [288]. 
TNFα and GM-CSF activate Erk1/2 in human polymorphonuclear leukocytes (PMNs), 
while G-CSF activates Erk1/2 in haematopoietic cells from STAT3 null mice [279]. 
 
The functions of Akt, STAT3 and Erk1/2 in Response to G-CSF Stimulation 
G-CSF is predominantly known for its ability to stimulate proliferation via activation of 
STAT signalling [289]. STAT3, the most studied in response to G-CSF activation, is 
required for G-CSF mediated proliferation and differentiation of myeloid cells [202]. 
STAT3 is recruited to the tyrosine residue Y704 of the G-CSFR where it is 
phosphorylated by JAK [289]. Deletion of the membrane-distal Y729, Y744 and Y764 
of the G-CSFR leads to hyper-proliferative responses of bone marrow in mice [290]. 
Further mutations to the STAT3 recruitment site at Y704, abolish detectable STAT3 
activation and reduce granulopoiesis [291].  
 
Akt and Erk1/2 are less studied in relation to the actions of G-CSF. However, since the 
discovery of the G-CSFR in non-haematopoietic tissue, Akt and Erk1/2 are emerging as 
significant signalling modulators of G-CSF action. The Src-family members Lyn and 
Hck stimulate granulocyte proliferation and differentiation, respectively, in response to 
G-CSF stimulation in vitro [238, 239]. Lyn and Hck are upstream regulators of Akt with 
early experiments implicating Akt in G-CSF mediated control of cell survival in 
multipotent mouse progenitors [292]. However, more recent work suggests G-CSF is 
not sufficient to protect neutrophils from apoptosis via Akt [293]. Similarly, the role of 
Erk1/2 in G-CSF signalling is less defined but appears to have important functions in 
both proliferation and differentiation. Mutation in Y764 cause hyper-proliferative 
responses and delayed differentiation in a bone marrow cell line (32D) overexpressing 
the G-CSFR [294]. This is via Shc and Ras, implicating Erk1/2 for G-CSF mediated 
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differentiation. Erk1/2 phosphorylation is indispensable in G-CSF mediated 
proliferation of haematopoietic cells from STAT3 null mice [279], suggesting STAT3 
may be a negative regulator of Erk1/2 in G-CSF signalling [279].  
 
Outside the haematopoietic system, G-CSF is known to activate Akt, STAT3 and 
Erk1/2 [179, 295-297].  In neural tissue, Akt phosphorylation is increased in rodents 
models of ALS following eight week of G-CSF treatment [223]. This is associated with 
a 55 % increase in muscle fibre size and increased survival in ALS mice.  G-CSF 
increases the phosphorylation of Akt, STAT3 and Erk1/2 in neural tissue and has neuro-
protective effects in a rodent model of Huntington’s disease [298]. In cardiac tissue, 
increased activation of Akt and STAT3 signalling is observed following G-CSF 
treatment in a human-hamster model of dilated cardiomyopathy [299], and G-CSF 
protects against rodent myocardial ischemia-perfusion injury via Akt [183, 300]. In 
rodent skeletal muscle, Akt and GSK-3β phosphorylation is increased with G-CSF 
treatment after cardiotoxin induced necrosis [137]. This suggests G-CSF may bind 
directly to its receptor in skeletal muscle and activate the downstream signalling 
pathways associated with the G-CSFR/G-CSFR. Prior to 2011 it was unknown if G-
CSF directly activated Akt, STAT or Erk1/2 in skeletal muscle. In 2011, Hara et al 
showed G-CSF activated these signalling proteins in C2C12 myoblasts. It remained 
undetermined if G-CSF could activate these signalling proteins in skeletal muscle 
myotubes.  
 
1.2.7 G-CSF and Inflammation 
Inflammatory cytokines including IL-1, IL-17, and TNFα and stress-responsive 
bacterial proteins induce G-CSF production in macrophages, endothelial cells, 
fibroblasts and mesenchymal cells [301-304]. G-CSF itself induces cytokine production 
of TNFα and GM-CSF in healthy volunteers [305]. Serum concentrations of G-CSF are 
virtually undetectable in healthy individuals [306], however rise significantly in 
response to a stress stimulus such as a bacterial infection or cellular damage [307]. G-
CSF gradually falls back to negligible levels during recovery [308, 309]. Its role in 
mobilising neutrophils has labelled it a pro-inflammatory cytokine. However, G-CSF 
has important anti-inflammatory properties. Systemically, G-CSF protects rodents 
against lipopolysaccharide (LPS) induced toxicity via suppression of systemic TNFα 
[310]. In whole blood, LPS induces a pro-inflammatory response, which is blunted by 
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the addition of G-CSF ex vivo [311]. Interestingly, Ibuprofen users have markedly (12-
fold) increased G-CSF circulating levels following long duration endurance exercise 
[312], suggesting that G-CSF may have anti-inflammatory properties in response to 
skeletal muscle damage. Whether G-CSF modulates the inflammatory response in 
cultured skeletal muscle remains to be determined.  
 
Interestingly, circulating G-CSF levels are increased in the blood stream following 
eccentric muscular contraction [115, 313]. Similarly, human primary skeletal muscle 
myotubes produce G-CSF when mechanically stretched to cause cellular damage [116]. 
However, it currently is unknown if G-CSF is produced locally within the muscle 
following exercise-induced damage. In BAF/3 cells stably transfected with the G-
CSFR, G-CSF stimulates ROS production and increases proliferation [314]. A powerful 
antioxidant and anti-inflammatory agent, N-Acetyl Cysteine (NAC) [315] inhibits the 
actions of G-CSF on these cells and reduces ROS production and proliferation. In 
skeletal muscle, NAC inhibits fatigue [316] and blunts the reduction in muscle force at 
24 and 48 hours following eccentric exercise [317], presumably by scavenging 
superoxides and limiting oxidative stress. However, long term recovery is hampered in 
subjects receiving NAC supplementation [317]. Therefore, NAC treatment may inhibit 
G-CSF production following eccentric damaging exercise and may partially explain the 
reduced recovery in force production seen in these participants.  
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1.3 Summary and Significance 
Skeletal muscle atrophy is a devastating condition and a characteristic of many disease 
states such as cancer, neuromuscular diseases, heart disease, COPD, sepsis and AIDS 
[7]. Secondary muscle atrophy is seen as one of the most potent stimuli restricting 
treatment and recovery [7, 52, 53]. As a result, muscle atrophy is a strong predictor of 
morbidity and mortality associated with these diseases. Therefore, developing 
therapeutic agents and understanding the molecular and physiological contributions to 
the regulation of skeletal muscle is a prerequisite for improving clinical outcomes. 
Recently G-CSF emerged as a potential therapeutic agent. 
 
G-CSF is widely known for its ability to stimulate the mobilisation of haematopoietic 
stem cells from the bone marrow [152, 154], stimulate survival, proliferation, and 
differentiation of granulocytic precursors and activation of neutrophils [155, 156]. 
Signal transduction occurs via the G-CSFR that is present on many cell types including 
those outside the haematopoietic system [138, 224, 318, 319]. In non-haematopoietic 
tissue, G-CSF treatment stimulates cardiac myocyte proliferation [206] and neural cell 
differentiation [222], and is associated with activation of Akt, STAT3 and Erk1/2 in 
vitro. In skeletal muscle, G-CSF improves muscle strength following injury in rodents 
[136]. The enhancement of muscle function is preceded by a significant increase in 
satellite cell proliferation, decreased apoptosis, increased regeneration, and higher 
muscle protein content. In other rodent models, G-CSF increases muscle repair 
following a local CTX injection [137] and activates Akt, STAT3 and Erk1/2 in C2C12 
myoblasts in vitro [138]. G-CSF increases motor function, muscle mass and muscle 
fibre size in SOD1tg mice [223]. Therefore, G-CSF may be a promising therapeutic 
compound to ameliorate skeletal muscle atrophy. The signalling pathways known to 
propagate the effects of G-CSF in haematopoietic cells, neural tissue and cardiac 
myocytes are of vital importance in skeletal muscle. Thus, G-CSF may bind to its 
receptor in skeletal muscle. However, the molecular mechanisms by which G-CSF 
regulates skeletal muscle have not clearly been established. The knowledge obtained 
from these studies will increase the understanding of how G-CSF may improve muscle 
health and provide important evidence supporting its use as a therapeutic agent to 
promote muscle repair and function following trauma and/or disease. 
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1.4 Aims and Hypotheses 
 
The broad aim of this PhD thesis is to determine the regulation of G-CSF/G-CSFR in 
skeletal muscle and to understand the molecular mechanisms of G-CSF function in 
skeletal muscle.  
 
1.4.1 Aims 
The Specific aims of this thesis are: 
 
1. a) To determine if the G-CSFR is expressed in skeletal muscle and  
b) to investigate the expression levels of G-CSF/G-CSFR in diseased skeletal 
muscle. 
 
2. a) To determine if G-CSF effects myoblast proliferation and/or differentiation  
b) To determine if G-CSF activates the signalling proteins Akt, STAT3 and 
Erk1/2 in C2C12 myoblasts. 
 
3. a) To determine if G-CSF effects protein degradation and protein synthesis 
under basal and catabolic conditions  
b) To determine if G-CSF activates the signalling proteins Akt, STAT3 and 
Erk1/2 in C2C12 myotubes. 
 
4. a) To determine if G-CSF modulates the inflammatory profile of C2C12 
myotubes following LPS induced inflammation and  
b) To determine if G-CSF/G-CSFR is altered in skeletal muscle following 
eccentric muscle damage with and without anti-inflammatory (N-acetylcycstene 
(NAC)) supplementation. 
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1.4.2 Hypothesis 
It is hypothesised that: 
 
1. a) The G-CSFR is expressed in skeletal muscle  
b) G-CSF and the G-CSFR levels will be increased in diseased skeletal muscle. 
 
2. a) G-CSF will increase C2C12 myoblast proliferation and differentiation.  
b) G-CSF will activate the signalling proteins Akt, STAT3 and Erk1/2 in C2C12 
myoblast cultures. 
 
3. a) G-CSF will protect against protein degradation and protein synthesis under 
catabolic conditions. 
b) G-CSF will activate the signalling proteins Akt, STAT3 and Erk1/2 in C2C12 
myotube cultures. 
 
4. a) G-CSF will modulate the inflammatory profile of C2C12 myotubes to 
resemble an anti-inflammatory profile following an inflammatory challenge.  
b) G-CSF will be increased in the muscle following eccentric muscle damage 
and NAC will increase this response. The G-CSFR expression will be increased 
following skeletal muscle damage caused by eccentric exercise. 
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CHAPTER TWO 
 
The Identification of the G-CSFR and 
Characterisation of G-CSF/G-CSFR in Healthy and 
Diseased Skeletal Muscle 
 
2.1 Introduction 
Skeletal muscle atrophy is a devastating condition and a characteristic of many disease 
states such as cancer, neuromuscular diseases, heart disease, chronic obstructive 
pulmonary disease (COPD), sepsis and AIDS [7]. Muscle atrophy is seen as one of the 
most potent stimuli restricting treatment and recovery [7, 52, 53]. As a result, muscle 
atrophy is a strong predictor of morbidity and mortality associated with cardiovascular, 
musculoskeletal, nervous, renal and respiratory diseases and cancers which are among 
the leading causes of death worldwide [54, 55]. Therefore, understanding the molecular 
and physiological contributors regulating muscle regeneration and muscle growth is a 
prerequisite for the development of therapeutic strategies aimed at improving clinical 
outcomes and reducing the burden on our health-care system.  
 
G-CSF is a cytokine whose primary functions are to stimulate the proliferation of bone 
marrow derived granulocytes and stem cells, and to drive the maturation of neutrophils 
[151]. G-CSF is routinely used to boost the immune system for patients undergoing 
cancer [139-141] and HIV treatment [148], for bone marrow or stem cell transplants 
[142, 143], stem cell donations and in the treatment of blood disorders [144-147]. 
Furthermore, G-CSF treatment stimulates the proliferation of cardiomyocytes [320] and 
lessens the severity of ischemic heart disease, acute myocardial infarction and chronic 
heart failure [183, 184, 188, 321]. In skeletal muscle, G-CSF treatment can increase 
recovery, activate satellite cells and increase muscle mass following crush injury [136]. 
G-CSF also increases muscle repair following a local cardiotoxin (CTX) injection [137] 
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and increases muscle function in rodent models of amyotrophic lateral sclerosis (ALS) 
[223].   
 
G-CSF exerts its effects by binding to its receptor (G-CSFR) on target cells. Once 
thought to be expressed only in haematopoietic stem cells, the G-CSFR has now been 
identified in a wider range of tissues including neural tissue [223, 322, 323], liver stem 
cells [179] and cardiac tissue [183, 184, 188, 320, 321]. Similarly, the G-CSFR has 
been identified in muscle precursor cells, retinal muscle tissue and muscles of the 
tongue during embryonic development [205, 324]. However, the G-CSFR has not been 
identified in skeletal muscle. 
 
The G-CSFR is expressed in diseased tissues which do not normally express the 
receptor under healthy conditions. Over 90% of ovarian cancers express the G-CSFR 
[215, 216] while bladder cancers express the G-CSFR during early formation [217-219]. 
Epithelial cells express the G-CSFR, however epithelial cancers show elevated G-CSFR 
expression [220]. Furthermore, the G-CSFR is significantly elevated in the 
cerebrospinal fluid (CSF) of ALS patients [181] and G-CSFR mRNA is increased in the 
brain following hypoxia-ischemia in neonatal rats [323]. Moreover, G-CSFR mRNA is 
elevated in neural tissue from rodent models of the neuromuscular disease amyotrophic 
lateral sclerosis (ALS) [223]. Whether the expression of the G-CSFR is altered in 
diseased skeletal muscle is unknown.   
 
The primary aim of this study was to identify and characterise the G-CSFR in healthy 
skeletal muscle. As of April, 2011 it remained undetermined if the G-CSFR was 
expressed in skeletal muscle. During the preparation of this thesis, the G-CSFR was 
identified in C2C12 myoblasts [138]. Regardless, the G-CSFR had not been characterised 
in diseased skeletal muscle and therefore remained an aim of this study. 
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2.2 Methods 
2.2.1 Tissue Extractions 
Human muscle biopsies 
The muscle biopsy procedure was approved by the Deakin University Human Research 
Ethics Committee in accordance with the Declaration of Helsinki (2000). Skeletal 
muscle samples were obtained from a 25 year old healthy male volunteer under local 
anaesthesia (1 % Xylocaine) from the belly of the vastus lateralis muscle using a 
percutaneous needle biopsy technique [325] modified to include suction [326]. 
Following a small incision through the skin, muscle biopsies were taken using a 
Bergstrom needle. Muscle samples were snap frozen in liquid nitrogen for RNA and 
protein extraction or used in the development of primary myoblast cultures as described 
below.  
 
mdx sample collection 
Diaphragm, soleus muscle and plasma samples from 8-9 week old C57Blk and mdx 
mice were a generous gift from Professor Gordon Lynch, Melbourne University. 
Briefly, soleus and diaphragm muscles were excised from the animals as previously 
described [327]. Whole blood was obtained by cardiac puncture and immediately spun 
at 4000 rpm for five minutes. The upper plasma phase was transferred to a sterile 
eppendorf tube and frozen at -80 °C. 
 
2.2.2 Cell Culture 
C2C12 cell cultures 
C2C12 Myoblasts (American Type Culture Collection (ATCC), Manassas, VA) were 
maintained at 37ºC, 5% CO2 in high glucose Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 10% foetal bovine serum (FBS) (Invitrogen, Carlsbad, 
CA). When cells were confluent and showing signs of spontaneous fusion, myoblasts 
were serum depleted in high glucose DMEM (Invitrogen) supplemented with 2% horse 
serum (HS) (Invitrogen) to form myotubes. 
 
Human primary cell cultures 
Approximately 150 mg of muscle tissue was used to establish primary human muscle 
cultures [328], with minor modifications. In brief, the muscle was extensively washed 
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and minced in ice-cold Hams F-10 medium (Invitrogen). The minced tissue was 
digested in 25 ml of 0.05% Trypsin/EDTA (Invitrogen) at 37°C with agitation for 20 
min to release the myoblasts into the collected supernatant. This process was repeated 
for a total of three digestions to break down the muscle tissue. Trypsin/EDTA was 
deactivated by the addition of 10% v/v HS (Invitrogen) followed by filtering of the 
supernatant through a pre-wet 74 μm filter. After centrifugation at 1600 rpm for 10 
minutes, the resulting cell pellet was re-suspended in Hams-F10 medium containing 
20% FBS, 25 ng/ml fibroblastic growth factor (FGF), 0.05% penicillin/streptomycin 
and 0.05% amphotericin (Invitrogen). The cells were seeded on to an uncoated 25 cm2 
tissue culture flask and incubated at 37°C for 30 minutes to induce fibroblast 
attachment, leaving myoblasts suspended in the medium. The medium was collected 
and myoblasts were re-seeded into an uncoated 25 cm2 tissue culture flask further 
repeating this step. The medium was then collected and seeded on to 25 cm2 tissue 
culture flask coated with an extracellular matrix (ECM). The resulting primary cell 
cultures were maintained in the human growth media in humidified air at 37 °C and 5 % 
CO2. At 70-80 % confluence differentiation was induced by serum depletion in DMEM 
with 2 % HS for 7-10 days. 
 
BAF/3 cell cultures 
BAF/3 cells, a pro-B mouse cell line stably transfected with the G-CSFR were grown in 
DMEM containing 10% v/v conditioned WEHI-3B medium were used as a positive 
control. Every 2-3 days, cells were spun at 1000 rpm for five minutes and resuspended 
in fresh media. At this time to avoid overcrowding, cells were passaged at 
approximately 1:3. Before extractions cells were spun at 1000 rpm for five minutes. The 
medium was removed and cells were washed in phosphate buffered saline (PBS) and re-
spun at 1000 rpm for 5 minutes to form a cell pellet. Cells were extracted for RNA and 
protein as described below. 
 
HEK293T cell culture 
HEK293T cells (American Type Culture Collection (ATCC), Manassas, VA) were used 
as a negative control as they do not express G-CSFR mRNA or protein [329]. 
HEK293T cells were maintained at 37ºC, 5% CO2 in high glucose Dulbecco's Modified 
Eagle's Medium (DMEM) supplemented with 10% foetal bovine serum (FBS) 
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(Invitrogen, Carlsbad, CA). Medium was replaced every 48 hours until cells became 
confluent, at which time protein was extracted. 
 
2.2.3 Messenger RNA (mRNA) Expression 
RNA extraction 
Exactly 500 μl of TRI-Reagent® Soln. (Ambion Inc., Austin TX) was used to extract 
RNA from each cell culture sample or approximately 20-40 mg wet weight muscle 
tissue. Cells were detached from the culture plate by gentle scraping while muscle tissue 
was homogenised using a bench to bullet blender with silica beads. The homogenates 
were quenched on ice for five minutes. Approximately 100 μl of chloroform was added, 
and the homogenate was mixed by gently inverting. Samples were placed at room 
temperature for 10 minutes before being centrifuged at 13,000 rpm for 15 minutes. The 
clear upper phase was carefully removed and placed in a sterile eppendorf tube. 
Approximately 500 μl of isopropanol was added and the samples for 15 minutes at 
room temperature to facilitate RNA precipitation. To isolate an RNA pellet, samples 
were centrifuged at 13,000 rpm for one hour. The supernatant was removed and the 
pellet washed with 75 % ethanol. The pellet was then re-suspended in 30 μl of nuclease 
free water (NFW). RNA concentration was determined using a NanoDrop® ND-1000 
spectrophotometer (NanoDrop products, Wilmington, DE). RNA was reverse 
transcribed (RT) to synthesise first strand cDNA using a high-capacity RNA-cDNA 
reverse transcription kit (Applied Biosystems, Foster City CA). Each sample was 
incubated with one unit of ribonuclease H (RNAse H) (Invitrogen) at 37 °C for 30 
minutes following reverse transcription. All cDNA was diluted to a working 
concentration of 5 ng/μl.  
 
Real Time quantitative PCR 
Primers were designed using Primer 3 (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) for the gene of interest. Sequences were designed and 
checked across exons using the Ensemble Genome Project (www.ensembl.org). The 
sequences were cross checked for gene specificity using a BLAST search 
(www.ncbi.nlm.gov/BLAST). Primers were synthesised by GeneWorks (Adelaide, SA). 
PCR primer details for the mouse genes are provided in Table 2-01. 
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A polymerase chain reaction (PCR) master mix containing 0.5 x SYBR® Green PCR 
Master Mix (Applied Biosystems) and the forward and reverse primers for the gene of 
interest was added to 25ng cDNA. The 20 μl reaction mix was loaded into a Thermo-
fast 96 Detection Plate (ABgene, Epsom UK). Real-Time PCR was performed using a 
Stratagene Mx3000p QPCR System (Stratagene, La Jolla CA) run by MxPro QPCR 
Software (Stratagene). All primers were used at 300 nM with an annealing temperature 
of 60 °C unless stated otherwise. 
 
Table 2-01 Human and mouse primer sequences. 
Primer 
GenBank 
accession no. Sense (5’-3’) Anti-sense (5’-3’) 
Human G-CSF NM_000759.3 GAG TTG GGT CCC ACC TTG TGG AAA GCA GAG GCG AAG 
Human G-CSFR NM_000760.3 CCT GCA TCA TCA AGC AGA AC AGT TCA GGA AGC AGG AGA GA 
Mouse G-CSF NM_009971.1 CGT TCC CCT GGT CAG TGT C CCG CTG GCC TGG ATC TTC 
Mouse G-CSFR NM_007782.3 TCA TGG CCA CCA GTC GAG C CACGCTGGAGTCCCAGAAG 
Mouse 36B4 NM_007475.5 TTGTGGGAGCAGACAATGTG AGTCCTCCTTGGTGAACACG 
 
 
DNA Gel Extraction and Sequencing 
In identifying the G-CSFR, PCR products from C2C12 myoblasts, C2C12 myotubes, the 
tibialis anterior and diaphragm from C57Blk mice, human primary myoblasts, human 
primary myotubes, human vastus lateralis and BAF/3 cells were separated on a 1.8% 
agarose gel containing 0.5 x SYBR® Safe DNA Gel Stain (Invitrogen). Images were 
captured using the Kodak Gel Logic 112 image station (Kodak Scientific Imaging 
Systems, Rochester, NY) under 302 nm UV light. The cDNA fragment was purified 
using the QIAquick Gel Extraction Kit (QIAGEN, Clifton Hill, Victoria, Australia) 
according to the manufacturer’s protocol. The purified cDNA was sequenced by the 
Australian Genome Research Facility (AGRF, Parkville, Melbourne).  
 
2.2.4 Protein Expression 
Protein Extraction 
Total protein was extracted from muscle tissue and cell culture using 1x 
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radioimmunoprecipitation (RIPA) buffer (Millipore, North Ryde, NSW) with one 
μL/mL protease inhibitor cocktail (Sigma-Aldrich, Castle Hill, NSW) and 10 μL/mL 
Halt Phosphatase Inhibitor Single-Use Cocktail (Thermo Scientific, Rockford, IL).  For 
cell culture, protein was homogenised by gently scraping in 100 μl extraction buffer, 
while muscle tissue samples were homogenised using a held homogeniser in 15 μl 
extraction buffer per mg wet weight. Samples were centrifuged at 13,000 rpm for 15 
minutes with the supernatant transferred to a clean eppendorf tube. Protein 
concentrations were determined from the development of a standard curve using the 
bicinchoninic acid (BCA) Protein Assay Kit (Pierce Biotechnology, Rockford, IL) 
according to the manufacturer’s protocol. 
 
Protein Deglycosylation 
Protein Deglycosylation was performed using the PNGase F (New England Biolabs, 
Ipswich, MA) according to the manufacturer’s protocol. In brief, 20 μg total protein was 
denatured in 1 x Glycoprotein denaturing buffer at 100 °C for 10 minutes. Following 
denaturing 1 x G7 reaction buffer, 2 μl 10 % NP-40 and 2 μl PNGase F was added to 
the protein sample. The sample was incubated using a water bath at 37 °C for 1 hour. 
The samples were frozen at -80 °C for western blot analysis. 
 
Western Blotting 
Electrophoresis was performed using a 4-12 % NuPAGE® Novex Bis-Tris Gel 
(Invitrogen) in NuPAGE® SDS MOPS Running Buffer (Invitrogen). Proteins were 
transferred to a PVDF membrane (Millipore) in a Bjerrum buffer containing 50 mM 
Tris, 17 mM glycine and 10 % methanol. The membranes were blocked with 5 % BSA 
in PBS, after which they were incubated overnight at 4 °C with G-CSFR (1:1000) 
(Santa Cruz Biotechnology, USA) diluted in PBS containing 5 % BSA. Following 
washing, the membranes were incubated with goat anti-rabbit IgG antibody (1:5000) 
labelled with an infrared-fluorescent 800 nm dye (Alexa Fluor® 800, Invitrogen), in 
PBS containing 50 % Odyssey® blocking buffer (LI-COR Biosciences, Lincoln, USA) 
and 0.01 % SDS. After washing, the proteins were exposed on an Odyssey® Infrared 
Imaging System (LI-COR). GAPDH (1:5000) (G8795, Sigma-Aldrich, Australia) and 
rabbit anti-mouse IgG antibody labelled with an infrared-fluorescent 680 nm dye (Alexa 
Fluor® 680, Invitrogen) was used as a loading control.  
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Cytokine Analysis 
A Milli-plex assay (Millipore) was used to analyse the protein expression of G-CSF 
cytokine within the skeletal muscle, diaphragm and plasma samples. The cytokine 
detection kits were designed for the analysis of a single cytokines, G-CSF, and the assay 
was conducted following the manufacturer’s protocol (Millipore). Briefly, the supplied 
standards were diluted for running a high sensitivity range (High PMT). The samples 
and standards were added to a 96 well plate containing the premixed beads coated with 
the target antibody. Following 30 minute incubation, plates were washed three times in 
wash buffer, and incubated with pre-mixed detection antibodies. Wells were then 
washed and incubated with streptoavidin-phycoerythrin. After a final series of washes 
samples were resuspended in 125 μl of assay buffer. The plate was read on the Bio-Plex 
Suspension Array System (V.5.0, Bio-Rad). For skeletal muscle and diaphragm tissue, 
samples were extracted according to the protein extraction method described above and 
diluted to 1000 μg/ml prior to the assay. Plasma samples were run undiluted. Intra-assay 
coefficient of variations (CV%) were 4.2 % for the plasma and 7.1 % for the diaphragm.  
 
2.2.5 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 4.1 (GraphPad Software, San 
Diego, CA). Means were compared between control and mdx using unpaired t-tests with 
significance set at p < 0.05.  
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2.3 Results 
2.3.1 Identification of the G-CSFR in skeletal muscle 
Using primers designed against the G-CSFR, an expected cDNA fragment of 
approximately 200 base pairs was observed in mouse and human muscle (Figure 2-
01A). Sequencing confirmed the mRNA expression of the G-CSFR in cultured C2C12 
myoblasts and myotubes, human primary myoblasts and myotubes and skeletal muscle 
tissue from both mouse and human samples. 
Using a polyclonal antibody raised against amino acids 25-200 mapping near the N-
terminus of G-CSFR of human origin (Santa Cruz), western blotting confirmed protein 
expression of the G-CSFR in skeletal muscle (Figure 2-01B). Using BAF/3 cells stably 
expressing the G-CSFR as a positive control, multiple glycosylation sites were 
confirmed in mouse C2C12 and human primary myoblasts and myotubes and in mouse 
and human skeletal muscle tissue (Figure 2-01B).  A westernblot using HEK293T cell 
which do not express G-CSFR [329] was used as a negative control (Figure 2-01C).  
 
Figure 2-01 Identification of the G-CSFR in rodent and human skeletal muscle. (A) RT-PCR 
fragment amplified using the primers described in table 2.1 separated on a 1.8% Sybr safe 
(Invitrogen) agarose gel and exposed to UV light.  (B) Western blot image identifying the G-CSFR 
in rodent and skeletal muscle in vitro and ex vivo. (c) Westernblot of HEK293T cells which are 
negative for the G-CSFR and BAF/3 overexpressing the G-CSFR 
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To confirm the bands identified by the anti-G-CSFR antibody were glycosylated, 
protein lysates were incubated with PGNase. PGNase reduced the band intensity at 
110kDa in C2C12 myoblasts, C2C12 myotubes, rodent (C57Blk) and human skeletal 
muscle homogenates (Figure 2-02).  
 
Figure 2-02 Deglycosylation of the G-CSFR. The G-CSFR exists in skeletal muscle in a non-
glycosylated isoform of approximately 85kda and a glycosylated isoform of approximately 110kDa. 
De-glycosylation with PGNase reduced the intensity of the 110kDa band in C2C12 myoblasts and 
myotubes as well as in murine and skeletal muscle. GAPDH was used as a loading control.  
 
To assess the expression of the G-CSFR through C2C12 differentiation, myoblasts were 
seeded and allowed to reach confluence over 2 days (days 1-2). C2C12 cells were 
differentiated by serum depletion (days 3-7). A time course assay revealed the G-CSFR 
protein is expressed in C2C12 myoblasts and is elevated 24 hours post serum depletion. 
The G-CSFR remained expressed in terminally differentiated C2C12 myotubes (Figure 
2-03).  
 
Figure 2-03 Characterisation of the G-CSFR during C2C12 myogenesis. At day 1 C2C12 cells are 
proliferating mononuclear cells undergoing mitosis. By the end of day 2 myoblasts have become 
confluent and begin to fuse into multinuclear myotubes. After Day 2 cultures are serum depleted to 
encourage differentiation. By day 7 terminally differentiated C2C12 myotubes have formed. 
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2.3.2 The Regulation of G-CSF and the G-CSFR in mdx Mice. 
The mRNA for G-CSF is significantly reduced in the tibialis anterior muscle (TA) and 
the diaphragm from 8-9 week old mdx mice when compared to littermate controls 
(Figure 2-04A and 2-04B). In contrast the G-CSFR mRNA is significantly elevated 8-
fold and >15-fold in the TA and diaphragm, respectively, in mdx mice compared to 
control mice (Figure 2-04 C and 2-04 D). 
 
 
Figure 2-04 mRNA expression of G-CSF and the G-CSFR mRNA in the tibialis anterior and 
diaphragm muscle from mdx mice. (A) G-CSF mRNA in the TA of mdx mice compared to 
control littermate. (B) G-CSF mRNA in the diaphragm of mdx mice compared to control 
littermates. (C) G-CSFR mRNA in the TA of mdx mice compared to control littermate. (D) G-
CSFR mRNA in the diaphragm of mdx mice compared to control littermates. mRNA was 
normalised to cDNA content using Oligreen ssDNA. Data is Mean ± SEM with significance 
indicated by **p<0.01 and ***p<0.001 (n=10) 
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Circulating G-CSF levels were significantly elevated in the mdx mouse compared to 
littermate controls (p<0.05) (Figure 2-05A). While G-CSF levels were below the 
detectable limits of the assay for the TA (data not shown), the G-CSF levels in the 
diaphragm coincided with the mRNA, and was significantly reduced (Figure 2-05B). 
There was no change in G-CSFR protein expression for the glycosylated isoforms of the 
G-CSFR. However, in contrast to the mRNA, the 85 kDa G-CSFR levels were 
significantly reduced in both the TA and diaphragm muscles of the mdx mouse (p<0.05) 
(Figure 2-05C and 2-05D).  
 
 
Figure 2-05 G-CSF and the G-CSFR protein expression in the mdx mouse. (A) Circulating 
plasma G-CSF levels (B) G-CSF levels in the diaphragm from control and mdx littermates. (C) 
Westernblot analysis for the G-CSFR in tibialis anterior (TA) and (D) the diaphragm muscle 
diaphragm muscle from mdx and control littermates. Graphical representation for the G-CSFR is 
for the ~85kDa band. Data is Mean ± SEM with significance indicated by * p <0.05 and *** p 
<0.001. (n=10 for cytokine analysis and n = 8 for western blotting). 
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2.4 Discussion  
G-CSFR expression has recently been identified in tissues outside the haematopoietic 
system [319]. In skeletal muscle, G-CSF treatment improves muscle recovery post 
trauma [136, 138]. G-CSF and the G-CSFR levels are also altered in various disease 
tissues [215, 223, 226, 318, 330]. Therefore, the present study aimed to characterise G-
CSF and the G-CSFR in diseased skeletal muscle. Several novel findings were 
observed. Firstly, the G-CSFR was identified in C2C12 and human primary myoblasts 
and myotubes and in mature skeletal muscle. Secondly, in a rodent model of DMD, the 
mdx mouse, G-CSF mRNA and protein was down-regulated in the diaphragm and 
tibialis anterior (TA) muscle. However, the G-CSFR was differentially regulated in 
mdx diaphragm and TA muscle; mRNA expression was increased while protein 
expression was decreased.  
 
The identification of the G-CSFR outside tissues of haematopoietic origin has 
significant clinical relevance. Identifying the G-CSFR in cardiac myocytes [206] has 
seen the administration of recombinant G-CSF progress from rodent models [183, 184, 
188, 321], to clinical trials as a therapy to combat cardiac remodelling following an 
infarct [190]. The current study identified mRNA and protein expression for the G-
CSFR in skeletal muscle. During the preparation of this thesis, Hara et al [138] also 
identified the G-CSFR receptor in skeletal muscle. However there were significant 
differences between these findings. Firstly, the current study identified mRNA 
expression of the G-CSFR using RT-PCR in C2C12 and human primary myoblasts, but 
in contrast to Hara et al [138] the current study identified G-CSFR mRNA in terminally 
differentiated myotubes. This was confirmed by mRNA sequencing and western 
blotting techniques to identify protein expression. In the present study multiple bands 
were detected between approximately 85 kDa and 110 kDa. This is in correlation to 
previous research using whole human bone marrow where the multiple bands for the G-
CSFR were detected between approximately 85 kDa and 120 kDa [331]. Furthermore, 
the banding patterns matched a positive control cell line, (BAF/3 cell), which stably 
express the G-CSFR. The molecular weight of the G-CSFR is stated to be 
approximately 90 kDa, however multiple glycosylation sites sees the protein display 
multiple bands in western blotting [198]. Hara et al [138] detected the G-CSFR in C2C12 
myoblasts using western blotting and immunofluorescent microscopy. Hara et al [138] 
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identified only a single band for the G-CSFR at 110 kDa. It has previously been shown 
that the antibodies for the G-CSFR are not specific for immunohistochemistry [329]. 
Therefore, results in Hara et al [138] from immunofluorescence staining need to be 
viewed with caution. 
 
Duchene’s Muscular Dystrophy (DMD), a severe neuromuscular disease is caused by a 
deletion in the cytoskeletal protein dystrophin, which destabilises the membrane and 
leaves the myofibre vulnerable to damage [332]. The mdx mouse, a widely studied 
mouse model for human DMD [333, 334], shows severe muscle myopathy characterised 
by progressive cycles of muscle degeneration and regeneration, chronic inflammation 
and necrosis [335]. In this model, G-CSF mRNA was significantly reduced in the TA 
muscle and diaphragm. While undetectable in the TA, the ligand followed a similar 
pattern to the mRNA and was down in the diaphragm. In contrast, circulating G-CSF 
levels were elevated in mdx mice. mdx mice have increased perfusion to the muscle 
[336]. Therefore an increase in circulating G-CSF would suggest an increase in tissue 
G-CSF. However, the observed reduction in G-CSF suggests that circulating G-CSF 
levels are independent of the muscle tissue levels. The elevations observed in 
circulation may simply be as a result of chronic inflammation seen in mdx mice. mdx 
mice have increasing inflammatory cytokines TNFα and IL-1β [337] that are known to 
induce G-CSF production in macrophages, endothelial cells, fibroblasts and 
mesenchymal cells [301-304]. The increased circulating G-CSF may produce a 
feedback loop reducing G-CSF production and release into circulation at the tissue 
level. A second explanation could be that increased circulating G-CSF is entering into 
the muscle bed and being internalised as the G-CSF/G-CSFR complex upon ligation 
[166]. The G-CSF ligand-receptor complex is degraded by both the proteasome and 
lysosome following internalisation and ubiquitination [338, 339]. This could explain the 
decreased in G-CSFR protein levels, while auto-regulation of the receptor could explain 
the increase in G-CSFR mRNA at the tissue level. More likely, the degeneration seen in 
the mdx muscle and damage to the sarcolemma is reducing G-CSFR surface expression 
producing a feedback loop increasing G-CSFR mRNA expression. 
 
In conclusion, this study has shown for the first time that the G-CSFR is expressed in 
C2C12 myotubes, human primary myoblasts and myotubes cultures, and is expressed in 
mature skeletal muscle tissue. Secondly, the G-CSF mRNA is down-regulated in the 
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mdx muscle while the G-CSFR mRNA is up-regulated. However, both the G-CSF and 
G-CSFR protein are down-regulated at the tissue level in the mdx mouse. The role of 
altered G-CSF / G-CSFR levels in mdx mice needs to be further explored. Since, G-CSF 
treatment in ALS mice leads to increased life span and an increase muscular function 
and muscle size; it is not implausible to suggest the same beneficial effects could be 
observed in the mdx mouse.   
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CHAPTER THREE 
 
The Role of G-CSF in Proliferation and 
Differentiation of C2C12 Cells 
 
3.1 Introduction 
Proliferation of myoblasts is an important process for the long term health of skeletal 
muscle. Proliferation of myoblasts accomplishes two important features of skeletal 
muscle plasticity; (1) the replenishment of the satellite cell pool where one daughter cell 
returns to quiescence while (2) the active regeneration of skeletal muscle by fusing with 
the injured myofibril upon differentiation. There are a number of significant stimuli that 
activate satellite cells from quiescence, and the proliferation of myoblasts. These 
include mechanical load, exercise, or damage-induced activation of cytokines [340].  
 
Granulocyte-colony stimulating factor (G-CSF), a widely used commercially available 
drug (Neupogen®, Filgrastim ®), is a cytokine that is emerging as a potential 
therapeutic agent following muscle damage [136, 137]. Treatment with G-CSF 
increases skeletal muscle regeneration and force recovery following crush injury in 
rodents [136]. Furthermore, G-CSF increases the number of BrdU positive cells within 
the basal lamina [136]. G-CSF administration in mice, facilitates muscle regeneration 
following a local cytotoxic injection [137]. This is associated with an increased number 
of cells expressing the myoblast marker, pax7 [137]. G-CSF belongs to a closely related 
cytokine family, the type I receptor superfamily, which includes interleukin-6 (IL-6) 
and leukaemia initiation factor (LIF) [194-196, 319]. IL-6 is required for the activation 
of satellite cells in rodents while both IL-6 and LIF increase proliferation of C2C12 
myoblasts in vitro [129, 269]. Therefore it is likely that G-CSF may directly increase 
myoblast proliferation. However, this remains to be determined. 
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Proliferation and differentiation of skeletal muscle myoblasts is controlled by a number 
of myogenic factors. Following proliferation, a differentiation stimulus causes cell cycle 
arrest and myoblast follow one of two paths [8]. Myoblasts which return to quiescence 
show a down-regulation of MyoD expression, while myoblasts committed to 
myogenesis have a down-regulation of Pax7 and elevated levels of myogenic regulatory 
factors such as MyoD and myogenin. G-CSF, while widely known for its proliferative 
capacity, induces differentiation in granulocytes, neutrophils and more recently in 
cardiac tissue [151, 319, 320, 341]. G-CSF mobilises cardiac cells and increases muscle 
specific proteins troponin and myosin heavy chain during differentiation, in mice 
following a cardiac infarction [342]. However, it is currently unknown if G-CSF 
treatment increases differentiation of skeletal muscle cells. 
 
Akt STAT3 and Erk1/2, well known regulators of skeletal muscle proliferation and 
differentiation [179, 295-297] are activated by G-CSF in vivo.  In a human model of 
dilated cardiomyopathy, G-CSF increases survival, function and remodelling of cardiac 
muscle in hamsters [299]. This is associated with increased activation of Akt and 
STAT3 signalling. Furthermore, following eight weeks G-CSF treatment (30 
μg/kg/day), ALS mice show increased Akt phosphorylation in neural tissue and a 55 % 
increase in muscle fibre size [223]. Rodents treated with a local cardiotoxin show an 
increase in Akt phosphorylation in regeneration skeletal muscle after G-CSF treatment 
[137]. However, it is currently unknown whether G-CSF directly activates Akt, STAT3 
and Erk1/2 in skeletal muscle myoblasts.  
  
The primary aim of this study was to determine if G-CSF increase myoblast 
proliferation and/or differentiation of C2C12 cells in vitro. A second aim of this study 
was to determine if G-CSF treatment phosphorylated the protein kinases Akt and Erk1/2 
and the transcription factor STAT3 in C2C12 myoblasts. In April 2011 Hara et al. 
showed that recombinant G-CSF increased the proliferation rate of C2C12 myoblasts in 
vitro while G-CSF treatment increased Akt, Erk1/2 and STAT3 phosphorylation. The 
effects of G-CSF on C2C12 differentiation in vitro remained a primary aim of this study. 
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3.2 Methods 
3.2.1 Cell Culture 
For proliferation C2C12 Myoblasts (American Type Culture Collection (ATCC), 
Manassas, VA) were seeded at a density of 50 cells per mm2 and incubated at 37 ºC, 5 
% CO2 in growth media consisting of High glucose Dulbecco's Modified Eagle's 
Medium (DMEM) supplemented with 10% foetal bovine serum (FBS) (Invitrogen, 
Carlsbad, CA). For differentiation myoblasts were seeded at a density of 4 x 104 per mL 
and incubated as above. For differentiation, when myoblasts were confluent, the 
medium was replenished with DMEM containing 2% horse serum.  
 
Under normal physiological conditions G-CSF levels are virtually undetectable in the 
serum [343]. During extreme conditions such as sepsis, G-CSF levels rise to around 0.4 
ng/ml [344], with some studies reporting patients with G-CSF levels around 3-4 ng/ml 
[345]. Furthermore, recombinant G-CSF can be administered subcutaneously or 
intravenously with maximal concentrations being reached after 2-8 hours with a peak  > 
40 ng/ml [170]. Therefore G-CSF was tested at concentrations of 0.4, 4, 40 and 100 
ng/ml. 
 
3.2.2 Proliferation 
Cells were allowed to attach overnight before being incubated with G-CSF DMEM 
supplemented with 10 % FBS or under serum deprived conditions (2 % BSA) for the 
indicated times. Media ± G-CSF was replenished every 24 hours. Proliferation was 
measured via 4’,6-Diamidino-2-phenylindole dihydrochloride (DAPI) and 5-bromo-2’-
deoxyuridine (BrdU) staining. 
 
DAPI 
After 24, 48, 72 and 96 hours C2C12 myoblasts were incubated with 0.1 μg/ml DAPI 
(Sigma-Aldrich, Castle Hill, NSW) stain for 10 minutes at room temperature. Images 
were obtained using the Olympus Fluoview FV10i confocal laser scanning microscope 
with dedicated software at a 10 x magnification. A minimum of ten images per group 
were analysed using ImageJ Software (National Institutes of Health, Bethesda, MA) to 
quantify the number of nuclei per image. 
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BrdU 
Myoblasts were assayed for BrdU incorporation using the 5-bromo-2’-deoxyuridine 
(BrdU) Labelling and Detection Kit III (Roche, Castle Hill, Australia) according to the 
manufacturer’s protocol. Briefly, following 24 and 48 hours of BrdU labelling (10 μM), 
myoblasts were fixed in 70 % ethanol in 0.5 M HCl at -20 °C for 30 minutes. Following 
a series of PBS washes containing 10 % calf serum, cells were incubated with the 
supplied nucleases at 37 °C in the absence of CO2 for 30 minutes. Again cells were 
washed and incubated with Anti-BrdU-POD, Fab Fragments for 30 minutes at 37 °C. 
After a final series of washes, peroxidase substrate with substrate enhancer was added to 
the wells and the substrate allowed to develop in the dark for 5 minutes. Absorbance 
was determined at a wavelength of 405 nm.  
 
3.2.3 Differentiation 
When myoblasts were confluent DMEM containing 2 % horse ± G-CSF was added to 
induce differentiation. Images were obtained every 24 hours for four days using an 
Olympus IX70 microscope (Olympus, Mt Waverly, VIC), and an attached DS-U3 
microscope camera with NIS-Elements imaging software (Nikon Instruments Inc., 
Melville, NY). At the same time points RNA was extracted from the cells. The media ± 
G-CSF was replenished every 24 hours throughout the experiment. 
 
RNA extraction and Real-Time Polymerase Chain Reaction (RT-PCR) 
Exactly 500 ul of TRI-Reagent® Soln. (Ambion Inc., Austin TX) was used to extract 
RNA from each well of a cell culture plate. Cells were detached from the culture plate 
by gentle scraping and immediately quenched on ice for five minutes. Approximately 
100 μl of chloroform was added and the homogenate vortexed for 30 seconds. Samples 
were placed at room temperature for ten minutes before being centrifuged at 13,000 rpm 
for 15 minutes. The clear upper phase was carefully removed and placed in a sterile 
eppendorf tube. Approximately 100 μl of isopropanol was added and the samples to 
facilitate RNA precipitation. To isolate an RNA pellet, samples were centrifuged at 
13,000 rpm for one hour. The supernatant was removed and the pellet washed with 800 
μl of 75 % ethanol in nuclease free water (NFW). The pellet was re-suspended in 30 μl 
of NFW. RNA concentration was determined using a NanoDrop® ND-1000 
spectrophotometer (NanoDrop products, Wilmington, DE). Exactly 2 μg of RNA was 
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reverse transcribed (RT) to synthesise first strand cDNA using a high-capacity RNA-
cDNA reverse transcription kit (Applied Biosystems, Foster City CA). Each sample was 
incubated with one unit of ribonuclease H (RNAse H) (Invitrogen) at 37 °C for 30 
minutes. All cDNA was diluted to a working concentration of 5 ng/μl.  
 
Primers were designed using Primer 3 (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) for the gene of interest. Sequences were designed and 
checked across exons using the Ensemble Genome Project (www.ensembl.org). The 
sequences were cross checked for gene specificity using a BLAST search 
(www.ncbi.nlm.gov/BLAST). Primers were synthesised by GeneWorks (Adelaide, SA). 
PCR primer details for the mouse genes are provided in Table 3.1. 
 
A polymerase chain reaction (PCR) master mix containing 0.5 x SYBR® Green PCR 
Master Mix (Applied Biosystems) and the forward and reverse primers for the gene of 
interest was added to 25 ng cDNA. The 20 μl reaction mix was loaded into a Thermo-
fast 96 Detection Plate (ABgene, Epsom UK). Real-Time PCR was performed using a 
Stratagene Mx3000p QPCR System (Stratagene, La Jolla CA). All primers were used at 
300 nM with an annealing temperature of 60 °C unless stated otherwise. To compensate 
for variations in final RNA concentrations due to pipetting  and reverse transcription 
efficency, data was normalized to single-stranded DNA (ssDNA) content, determined 
using the Quanti-iT OliGreen ssDNA Assay Kit (Molecular Probes, Eugene, OR) 
according to the manufacturer’s protocol. 
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Table 3-01 mouse primer sequences. 
Gene 
GenBank 
accession no. 
Forward Primer (5’-3’) Reverse Primer (5’-3’) 
G-CSF NM_009971.1 CGT TCC CCT GGT CAG TGT C CCG CTG GCC TGG ATC TTC 
G-CSFR NM_007782.3 TCA TGG CCA CCA GTC GAG C CACGCTGGAGTCCCAGAAG 
Mhc1 NM_080728.2 ACCCTCAGGTGGCTCCGAGA  TGCAGCCCCAAATGCAGCCA 
Mhc2a NM_001039545.2 GAGCAAAGATGCAGGGAAAG TAAGGGTTGACGGTGACACA 
Mhc2b NM_010855.2 ACAGACTAAAGTGAAAGCC CTCTCAACAGAAAGATGGAT 
Mhc2x NM_030679.1 GGACCCACGGTCGAAGTTGCA GGAACTCATGGCTGCGGGCT 
Myogenin NM_031189.2 TCCATCGTGGACAGCATCAC CAATCTCAGTTGGGCATGGTTT 
MyoD NM_010866.2 CTGCTTCTTCACGCCCAAA CTGGAAGAACGGCTTCGAAAG 
 
 
3.2.3 Protein Extraction and Western Blotting  
 
G-CSF Treatments and Protein Extraction 
At approximately 80 % confluence, myoblasts were serum starved in DMEM 
(Invitrogen) for four hours followed by stimulation with serum free media ± G-CSF. 
Total protein was extracted after 5, 10, 15, 30 and 90 minutes and phosphorylation was 
compared to basal levels following four hours serum starvation. Protein was extracted 
using 1x radioimmunoprecipitation (RIPA) buffer (Millipore, North Ryde, NSW) with 
one μl/ml protease inhibitor cocktail (Sigma-Aldrich, Castle Hill, NSW) and 10 μL/mL 
Halt Phosphatase Inhibitor Single-Use Cocktail (Thermo Scientific, Rockford, IL).  
Samples were centrifuged at 13,000 rpm for 15 minutes with the protein concentration 
of the supernatant determined from the development of a standard curve using the BCA 
Protein Assay Kit (Pierce Biotechnology, Rockford, IL) according to the manufacturer’s 
protocol.  
 
Western Blotting 
Electrophoresis was performed using a 4-12 % NuPAGE® Novex Bis-Tris Gel 
(Invitrogen, Carlsbad, CA) in NuPAGE® SDS MOPS Running Buffer (Invitrogen, 
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Carlsbad, CA). Proteins were transferred to a PVDF membrane (Millipore, North Ryde, 
NSW) in a Bjerrum buffer containing 50 mM Tris, 17 mM glycine and 10 % methanol. 
The membranes were blocked with 5 % BSA in PBS, after which they were incubated 
overnight at 4°C with the primary antibody diluted in 5 % BSA in PBS;  phospho-Akt 
(ser473), phospho-STAT3 (Tyr705), phospho-Erk1/2 (Thr202/Tyr204), Akt antibody, 
STAT3 antibody and Erk1/2 antibody (Cell Signalling Technology, Denvers, MA). 
Following washing, the membranes were incubated with the secondary antibody for 1 
hour which consisted of goat anti-rabbit IgG antibody (1:5000) labelled with an 
infrared-fluorescent 800 nm dye (Alexa Fluor® 800, Invitrogen) in PBS containing 50 
% Odyssey® blocking buffer (LI-COR Biosciences, Lincoln, NE) and 0.01 % SDS. 
Proteins were exposed on an Odyssey® Infrared Imaging System (LI-COR Biosciences, 
Lincoln, NE). After phospho protein exposure, the membranes were recovered and 
incubated in membrane stripping buffer (25 mM Glycine, 2 % w/v SDS; pH 2.0) three 
times for a total of 1 hour to remove the phospho antibody. Stripping efficiency was 
confirmed by incubation with the secondary antibody and protein exposure.  
 
3.2.4 Statistical Analysis 
Proliferation 
A one-way ANOVA was used to determine the interaction between treatment 
concentration (0, 0.4, 4, 40 and 100 ng/ml G-CSF) at each time point.  For BrdU 
analysis a two-way ANOVA was used to determine the interaction between G-CSF 
concentration (0, 0.4, 4, 40 and 100 ng/ml G-CSF) and treatment group (under normal 
growth conditions vs serum depletion). Newman-Keuls Multiple Comparison Test was 
used to determine differences between groups with significance set at p < 0.05, while 
a Bonferroni adjustment was used for the 2-way ANOVA. 
 
Differentiation 
A one-way ANOVA was used to determine the interactions of time (Day 1, 2, 3 and 4). 
Furthermore, a one-way ANOVA was used to determine the interaction between 
treatment concentrations (0, 0.4, 4, 40 and 100 ng/ml G-CSF) at each day.  Newman-
Keuls Multiple Comparison Test was used to determine differences between groups 
with significance set at p < 0.05. 
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Protein Analysis 
A one-way ANOVA was used to determine the interaction of time (0, 5, 10, 15, 30, 60 
and 90 mins) at the given concentration of G-CSF treatment. Furthermore a two-way 
ANOVA was used to determine an interaction between time (0, 5 and 15 mins) and 
treatment (Control and G-CSF). Newman-Keuls Multiple Comparison Test was used to 
determine differences between groups with significance set at p < 0.05. 
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3.3 Results 
3.3.1 Proliferation 
Following DAPI staining of the nuclei myoblasts were observed using confocal 
microscopy at 24 hour intervals over a 96 hours period (Figure 3-01). In growth media 
C2C12 myoblasts proliferated as expected, approximately doubling at 48 and 72 hours. 
By 72 hours myoblasts were confluent causing cell cycle arrest and spontaneous fusion 
under normal growth conditions (Figure 3-01A). In DMEM containing 2 % BSA 
(Figure 3-01B) C2C12 myoblasts proliferated slowly over the first 48 hours followed by 
the cessation of proliferation. No changes in proliferation were observed with the 
addition of G-CSF at 24, 48, 72 and 96 hours (Figure 4-01) under normal or serum 
depleted conditions. 
 
 
 
 
 
Figure 3-01 The effects of G-CSF on C2C12 myoblast proliferation. Proliferating C2C12 
myoblasts incubated in the indicated concentration of G-CSF under (a) normal growth media 
containing 10 % fetal bovine serum or (b) serum depleted growth media containing 2 % BSA. Data 
is Mean ± SEM. A minimum of 10 images were taken per sample (n=3).  
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Representative images following DAPI staining and cell counting of proliferating C2C12 
myoblasts in DMEM + 10 % FBS ± G-CSF at the indicated concentrations (Figures 3-
02)  
 
 
 
Figure 3-02 DAPI staining of proliferating C2C12 myoblast following G-CSF stimulation 
grown in 10% FBS. Representative images following DAPI staining of C2C12 myoblasts following 
24, 48, 72 and 96 hours in DMEM + 10 % FBS with the indicated concentration of G-CSF. A 
minimum of 10 images were obtained per sample (n=3)  
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Representative images following DAPI staining and cell counting of proliferating C2C12 
myoblasts in DMEM + 2 % BSA ± G-CSF at the indicated concentrations (Figures 3-
03)  
 
 
 
 
Figure 3-03 DAPI staining of proliferating C2C12 myoblasts following G-CSF treatment with 
serum depletion. Representative images following DAPI staining of C2C12 myoblasts following 24, 
48, 72 and 96 hours in DMEM + 2 % BSA with the indicated concentration of G-CSF. A minimum 
of 10 images were obtained per sample (n=3) 
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To confirm that G-CSF was not having any effect on proliferation BrdU was 
incorporated into the cellular DNA of proliferating C2C12 and quantified after 24 and 48 
hours. C2C12 cells grown in 10 % FBS (GM) incorporated more BrdU into their 
cellular DNA compared to serum depleted cells (BSA) after 24 and 48 hours. G-CSF 
did not have any effect on BrdU incorporation after 24 and 48 hours (Figure 3.04) 
 
 
 
Figure 3-04 BrDU incorporation into proliferating C2C12 myoblasts following G-CSF 
treatment. Proliferating C2C12 myoblasts in Growth Media (GM) containing DMEM + 10 % FBS 
(black bars) or DMEM + 2% BSA (white bars) following 0, 0.4, 4, 40 and 100 ng/ml G-CSF 
treatment for a) 24 hours and b) 48 hours. Data is Mean ± SEM, * p < 0.05 compared to GM. 
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3.3.2 Differentiation 
To induce differentiation confluent C2C12 myoblasts were serum depleted in DMEM 
containing 2 % HS. As expected C2C12 cells formed visible myotubes after 4 days 
(Figure 3-05A). This was confirmed by mRNA expression of the myosin heavy chains 
(I, IIa, IIb and IIx) which increased during myotube formation (Figure 3-05B). G-CSF 
mRNA transiently increased at day 2 by 20% (Figure 3-05B). There was no change to 
the G-CSFR 
 
 
 
Figure 3-05 Gene expression and light microscopy during C2C12 differentiation. (A) Light 
microscope images of C2C12 cells at 24 hour intervals during differentiation incubated under normal 
control conditions. (B) myosin heavy chains (MHC) 1, 2a, 2b, 2x, G-CSF and G-CSFR during 4 
days of differentiation. Data is represented as a fold change above day one compared to Day 1. 
Mean ± SEM, * p <0.05, ** p <0.01, *** p <0.001, n=3 
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At day 1 of differentiation there was no change to MHCI MHCIIa, MHCIIb, MHCIIx, 
myogenin, MyoD or G-CSF and the G-CSFR (Figure 3-06) 
 
 
Figure 3-06 Gene expression and light microscopy after day 1 of differentiation. (A) myosin 
heavy chains (MHC) 1, 2a, 2b, 2x, the myogenic regulatory factors myogenin and MyoD and G-
CSF, G-CSFR after 1 day of differentiation with and without G-CSF at 0, 0.4, 4, 40 and 100 ng/ml. 
Data is represented as Mean ± SEM as a fold change relative to the control (0 ng/ml G-CSF). (B) 
Representative light microscope images at day 1 with the indicated G-CSF concentration, n=3. 
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At day 2 of differentiation there was no change to MHCI MHCIIa, MHCIIb, MHCIIx, 
myogenin, MyoD or G-CSF and the G-CSFR (Figure 3-06) 
 
 
Figure 3-07 Gene expression and light microscopy after day 2 of differentiation. (A) myosin 
heavy chains (MHC) 1, 2a, 2b, 2x, the myogenic regulatory factors myogenin and MyoD and G-
CSF, G-CSFR after 2 day of differentiation with and without G-CSF at 0, 0.4, 4, 40 and 100 ng/ml. 
Data is represented as Mean ± SEM as a fold change relative to the control (0 ng/ml G-CSF). (B) 
Representative light microscope images at day 2 with the indicated G-CSF concentration, n = 3. 
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At day 3 of differentiation G-CSFR mRNA was significantly increased approximately 
2.5 fold with 100 ng/ml G-CSF (Figure 3-08A). There was no change to the G-CSFR 
with lower concentrations of G-CSF nor was there a change to G-CSF, MHCI MHCIIa, 
MHCIIb, MHCIIx, myogenin or MyoD mRNA expression (Figure 3-08).  
 
Figure 3-08 Gene expression and light microscopy after day 3 of differentiation. (A) myosin 
heavy chains (MHC) 1, 2a, 2b, 2x, the myogenic regulatory factors myogenin and MyoD and G-
CSF, G-CSFR after 3 day of differentiation with and without G-CSF at 0, 0.4, 4, 40 and 100 ng/ml. 
Data is represented as Mean ± SEM as a fold change relative to the control (0 ng/ml G-CSF). (B) 
Representative light microscope images at day 3 with the indicated G-CSF concentration, n = 3, * p 
< 0.05 compared to 0 ng/ml G-CSF. 
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At day 4 of differentiation G-CSFR mRNA was significantly increased approximately 
2.5 fold with 100 ng/ml G-CSF (Figure 3-09A). There was no change to the G-CSFR 
with lower concentrations of G-CSF nor was there a change to G-CSF, MHCI MHCIIa, 
MHCIIb, MHCIIx, myogenin or MyoD mRNA expression (Figure 3-09).  
 
Figure 3-09 Gene expression and light microscopy after day 4 of differentiation. (A) myosin 
heavy chains (MHC) 1, 2a, 2b, 2x, the myogenic regulatory factors myogenin and MyoD and G-
CSF, G-CSFR after 4 day of differentiation with and without G-CSF at 0, 0.4, 4, 40 and 100 ng/ml. 
Data is represented as Mean ± SEM as a fold change relative to the control (0 ng/ml G-CSF). (B) 
Representative light microscope images at day 4 with the indicated G-CSF concentration, n = 3, * p 
< 0.05 compared to 0 ng/ml G-CSF. 
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3.3.3 Protein Phosphorylation 
The Effects of G-CSF Treatment on Akt, STAT3 and Erk1/2 phosphorylation. 
C2C12 myoblasts were serum starved for four hours and protein was extracted from the 
control cells (time = 0 mins). Immediately prior to the start of the experiment serum free 
DMEM + G-CSF was added to the cells and protein was extracted at 5, 10, 15, 30 and 
90 minute intervals. 
 
Akt phosphorylation 
Following treatment, Akt phosphorylation was significantly increased by 5 minutes with 
all concentrations of G-CSF (Figure 3-10A-D). The greatest increase of 12.5-fold 
occurred with 40 ng/ml of G-CSF. Akt phosphorylation remained elevated following 90 
minutes of treatment independent of the G-CSF concentration used. 
 
Figure 3-10 Akt phosphorylation levels in response to G-CSF treatment in C2C12 myoblasts. 
Akt phosphorylation with A) 0.4 ng/ml, B) 4 ng/ml, C) 40 ng/ml and D) 100 ng/ml G-CSF 
treatment for 0, 5, 10, 15, 30 and 90 minutes. Data is Mean ± SEM, n = 3, * p <0.05 compared to 
time zero (0). 
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STAT3 phosphorylation 
Basal levels of phosphorylated STAT3 were low in C2C12 myoblasts following four 
hours serum starving. G-CSF did not increase STAT3 phosphorylation (Figure 3-11).  
 
 
 
 
Figure 3-11 The effects of G-CSF on STAT3 phosphorylation in C2C12 myoblasts. STAT3 
phosphorylation  with (A) 0.4 ng/ml, (B) 4 ng/ml, (C) 40 ng/ml and (D) 100 ng/ml G-CSF treatment 
for 0, 5, 10, 15, 30 and 90 minutes relative to total STAT3. +ve indicates a C 2C12 myotube protein 
lysate used as a positive control.  
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Erk 1/2 phosphorylation 
Erk-1 phosphorylation was significantly increased after 5 mins treatment with all 
concentrations of G-CSF (Figure 3-12A-D). The greatest increase of 8-fold was 
observed with 4 ng/ml G-CSF after 10 minutes. Erk-1 phosphorylation returned towards 
basal levels after 90 minutes independent of G-CSF concentration. 
 
 
Figure 3-12 The effects of G-CSF on Erk-1 phosphorylation in C2C12 myoblasts. Erk-1 
phosphorylation with (A) 0.4 ng/ml, (B) 4 ng/ml, (C) 40 ng/ml and (D) 100 ng/ml G -CSF treatment 
for 0, 5, 10, 15, 30 and 90 minutes. Data is Mean ± SEM, n = 3, * p <0.05 compared to time zero. 
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Erk-2 phosphorylation was significantly increased after 5 mins treatment independently 
of G-CSF concentration (Figure 3-13A-D). The greatest increase of 6.5-fold was 
observed with 40 ng/ml G-CSF after 10 minutes. Erk-2 phosphorylation returned 
towards basal levels after 90 minutes independent of G-CSF concentration. 
 
 
Figure 3-13 The effects of G-CSF on Erk-2 phosphorylation in C2C12 myoblasts. Erk-2 
phosphorylation with (A) 0.4 ng/ml, (B) 4 ng/ml, (C) 40 ng/ml and (D) 100 ng/ml G-CSF treatment 
for 0, 5, 10, 15, 30 and 90 minutes. The comparison between the media change effect  (Control) and 
40 ng/ml G-CSF. Data is Mean ± SEM, n = 3, * p <0.05 compared to time zero. 
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The Effects of Replenishing the Media on Akt, STAT3 and Erk1/2 Phosphorylation 
It has previously been shown that Akt and Erk phosphorylation are sensitive to stress 
associated with changing media in cardiomyocytes [346]. Therefore to determine if 
replenishing media influenced Akt and Erk1/2 phosphorylation, fresh serum free 
DMEM without G-CSF was added to C2C12 myoblasts following four hours serum 
starving. Protein was extracted at 5, 10, 15, 30 and 90 minutes following media 
replenishment and compared to time 0 control. Akt phosphorylation increased by 2.5 
fold after 10 minutes and remained elevated after 90 minutes (Figure 3-14A). Erk-1 and 
Erk-2 phosphorylation was elevated by 3-fold after 5 minutes (Figure 3-14B and Figure 
3-14C) 
 
Figure 3-14 The effects of changing media on Akt and ER1/2 phosphorylation C2C12 
myoblasts. Fold changes in phosphorylation for (A) Akt, (B) Erk-1 and (C) Erk-2 above time zero 
(0) control after replenishing the media. C2C12 myoblasts were 4 hour serum starved at time 0. Data 
is Mean ± SEM, n = 3, * p <0.05 compared to time zero. 
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Vehicle vs G-CSF treatment on Akt and Erk phosphorylation 
The previous results show that the stress associated with replenishing media was 
sufficient to increase Akt and Erk1/2 phosphorylation. It was therefore of interest to 
differentiate between the effect of replenishing media with that of G-CSF. To achieve 
this media was replenished after 4 hours of serum starving with either fresh serum free 
DMEM without (vehicle control) or with G-CSF (40 ng/ml). Both conditions 
significantly increased Akt phosphorylation by 2.5-fold and 6.5-fold when measured 5 
and 10 minutes after treatment, respectively (Figure 3-15A). Similarly, both conditions 
significantly increased Erk1 and Erk-2 phosphorylation by 5-fold and 8-fold, 
respectively after 5 and 10 minutes of treatment (Figure 3-15B-C). There was no 
difference between vehicle and G-CSF for Akt and Erk1/2 phosphorylation. 
   
Figure 3-15 Akt and Erk1/2 phosphorylation with 40 ng/ml G-CSF vs vehicle treatment. Fold 
changes in phosphorylation for (A) Akt, (B) Erk-1 and (C) Erk-2 above time zero control treated 
with 40 ng/ml G-CSF (black bars) or vehicle control (white bars). Data is Mean ± SEM, n = 3, * p 
<0.05 compared to time zero. 
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To confirm that G-CSF was not increasing Akt, STAT3 or Erk1/2 a spike in method 
was used. This method removes the confounding effects of the media change. C2C12 
myoblasts were serum starved for four hours prior to 20 μl G-CSF being added to the 
media to a final concentration of 40 ng/ml. Using this method G-CSF did not affect the 
phosphorylation of Akt, STAT3 or Erk1/2 (Figure 3-16).  
 
 
     
 
Figure 3-16 Akt, STAT3 and Erk1/2 phosphorylation with 40 ng/ml G-CSF. Representative 
images of Akt, STAT3 and Erk1/2 phosphorylation following stimulation with G-CSF (40 ng/ml) 
from 5 – 90 minutes. 20 μl G-CSF was added to the media at time 0 minutes. Time zero represents 
four hours after serum free media was added to the cells. Ins = 100 μM insulin treated C2C12 
myoblast 15 minutes using the spike in technique.  
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3.4 Discussion 
In rodents, G-CSF treatment increases muscle recovery from a crush injury [136] and 
increases muscle regeneration following a local cytotoxic injury [137], both of which 
allude to an increase in cell proliferation within the regenerating tissue. In Chapter 2 the 
G-CSFR was identified in skeletal muscle. Therefore this study aimed to determine if 
G-CSF stimulation could increase C2C12 myoblast proliferation and/or C2C12 
differentiation. Secondly, this study aimed to determine if G-CSF treatment could 
stimulate signalling pathways associated with the G-CSFR; Akt, Erk1/2 and STAT3 in 
C2C12 myoblasts. Several novel observations were made. Firstly, G-CSF treatment did 
not stimulate C2C12 myoblast proliferation. Secondly, G-CSF treatment did not affect 
the gene expression of myosin heavy chains (I, IIa, IIb and IIx) or the myogenic 
regulatory factors MyoD and myogenin during myotube formation. Thirdly, high dose 
G-CSF treatment increased G-CSFR mRNA at day 3 and day 4 during differentiation. 
And lastly, the increases in Akt, STAT3 and Erk1/2 in C2C12 myoblasts can be 
attributed to the effects of changing media and vehicle treatment and not to treatment 
with G-CSF in C2C12 myoblasts.   
 
This thesis clearly demonstrates that G-CSF does not stimulate C2C12 myoblast 
proliferation when myoblasts are stimulated with 0.4, 4, 40 and 100 ng/ml G-CSF in 
normal growth conditions (DMEM + 10% FBS) or serum depleted media (DMEM + 2 
% BSA). C2C12 myoblasts are known to proliferate and double approximately every 24 
hours [347]. The observations from the present study reflect this rate of proliferation, 
which was inhibited by serum depletion. Hara et al [138] show that G-CSF could 
increase C2C12 myoblast proliferation. However, they observed a reduction in myoblast 
cell number in the first 48 hours in the control group, which is untypical of proliferating 
C2C12 myoblasts. The conditions in which Hara et al [138] performed the proliferation 
experiment are not clearly described. It is not clear if proliferation was measured in the 
presence or absence of FBS, nor do they state at what confluence the cells were when 
G-CSF was added. Ultimately, a drop in cell number over the first 48 hours would 
indicate cell cycle arrest and induction of differentiation [348]. It could be argued that 
their results do not represent an increase in proliferation caused by G-CSF, but rather an 
inhibition of cell cycle withdrawal. However, even with the withdrawal of serum the 
current study did not see a drop in cell number after 24-48 hours. Hara et al [138] do 
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show that anti-G-CSF treatment reduces proliferation and conclude that G-CSF within 
the serum contributes to proliferation of C2C12 cells. However, in the present study G-
CSF did not increase C2C12 myoblast proliferation in the presence or absence of serum. 
Therefore, G-CSF alone is not sufficient to increase proliferation of C2C12 cells.  
 
The MRF myogenin is involved in myoblast commitment to myogenesis [21]. Myosins, 
a family of proteins known for their contractile properties in skeletal muscle, are 
significantly increased during myogenesis [349]. In the current study mRNA expression 
of myogenin was significantly increased at day two and remained elevated at day four. 
Similarly, mRNA for myosin heavy chains (I, IIa, IIb and IIx) continued to increase 
throughout differentiation. G-CSF had no influence over the mRNA expression of these 
genes at any time point.  However, 100 ng/ml G-CSF did increase G-CSFR mRNA 
expression at day 3 and day 4 of differentiation. This is consistent with in vivo studies 
which show increased levels of G-CSF mRNA are associated with increased G-CSFR 
mRNA [215, 223]. Similarly, C2C12 cells increase expression of other type I cytokine 
receptors such as the erythropoietin (EPO) receptor in response to incubation with their 
ligand [350]. This suggests that G-CSF may induce expression of its own receptor in a 
feed forward loop in C2C12 myotubes. However the significance of this remains 
unknown, and may be negligible. 100 ng/ml is significantly higher than what is 
observed following sepsis and i.p. injection in vivo [341]. Therefore G-CSF may not 
induce expression of its own receptor in skeletal muscle and in vivo experiments will be 
needed to determine the relevance of this finding. 
 
G-CSF is known to activate Akt, STAT3 and Erk1/2 in cells expressing the G-CSFR 
[202, 240]. In chapter 2 the G-CSFR was identified in C2C12 myoblasts and therefore it 
was hypothesised that G-CSF treatment could activate these proteins. Serum starving 
(3-20 hours) prior to experimental treatment is routinely used technique to reduce basal 
cellular activity [244, 351]. This study employed a four hour starvation period prior to 
treatment with or without G-CSF. Following serum starving, phosphorylation of Akt, 
Erk-1 and Erk-2 was at their lowest expression, while STAT3 was undetectable and 
remained undetectable for the 90 minutes in C2C12 myoblasts. In this study, re-
stimulating C2C12 myoblasts with DMEM following four hours serum starvation, 
significantly increased Akt and Erk1/2 phosphorylation with vast differences between 
experiments. Akt phosphorylation increased approximately 2.5-fold in one experiment 
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(figure 3-10A) and almost 15-fold (figure 3-10D) in another. One could be mistaken for 
interpreting this as an effect of increased activation from G-CSF, since G-CSF has been 
reported to stimulate Akt, STAT3 and Erk1/2 in C2C12 myoblasts [138]. This study 
showed no effect of G-CSF to stimulate these proteins above that of the control group 
when performed in the same experiment or when using a spike in method. The basal 
level of protein phosphorylation differs between cell lines and differs depending on the 
duration of serum starving [352]. For example Erk1/2 phosphorylation is significantly 
elevated by serum starving in human primary myotubes but significantly decreased in 
rat L6 myotubes [352]. p70s6K a downstream target of the PI3K/Akt/mTOR pathway is 
significantly elevated after 1-3 hours but significantly decreased after 12-24 hours 
[352]. Therefore, the common experimental method of serum starving between 3-20 
hours may produce significantly different basal levels of phosphorylation in C2C12 
myoblasts. In the current study, due to the large sample numbers needed to be collected 
to test the different concentrations of G-CSF, experiments were not all performed at the 
same time with the same passage of cells. This may potentially explain the range 
observed between experiments. Although steps were taken to minimise the differences 
between experiments, slight variation in cell confluence, the different passage cells or 
circadian rhythms may potentially explain these findings [353, 354]. 
 
The phenomenon of changing media has had minimal attention in the literature. 
However, one study assessing the actions of EPO shows treatment with the vehicle is 
sufficient to stimulate Akt in non-haematopoeitic tissues [346]. Results from this study 
demonstrate the importance of rigorous controls since media changes alone are 
sufficient to activate Akt, STAT3 and Erk1/2 phosphorylation. This is not unexpected 
since the constituents found in most cell culture medium contain known stimulants of 
Akt and Erk1/2 signalling such as glucose [355-357], amino acids [358, 359] and 
vitamins [360]. Hara et al [138] show activation of Akt, STAT3 and Erk1/2 with low 
concentrations (< 375 pg/ml) of recombinant G-CSF. This is significantly lower than 
the concentration of G-CSF used in most studies. Endothelial cells are activated with 
100 ng/ml G-CSF to stimulate angiogenesis [361]. Similarly, cardiomyocytes are 
stimulated with 100 ng/ml G-CSF to induce activation of JAK/STAT signalling and 
cardiac myocyte protection [206]. Cells which highly express the G-CSFR such as 
neutrophils and BAF/3 cells, are routinely stimulated with greater than 10 ng/ml G-CSF 
in vitro [362-366]. The methods employed by Hara et al [138] are not clear. They do not 
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show any control images for western blotting. Therefore the effects of the vehicle, 
serum activation or a media alone stimulating intracellular signalling cascades cannot be 
ruled out in that study. 
 
In conclusion, the current study demonstrates that G-CSF does not increase proliferation 
or differentiation of C2C12 myoblasts with concentrations ranging from 0.4 – 100 ng/ml. 
The actions of G-CSF may therefore require the interaction with tissue fragments or 
other cytokine and growth factors in vivo. For example G-CSF is known to cooperate 
with stem cell factor in haematopoiesis [367] and IL-6 during bone marrow stem cell 
tumour progression [368]. Furthermore G-CSF does not increase Akt, STAT3 or Erk1/2 
above that of the control. Here it is demonstrated that these signalling proteins are 
responsive to the effects of replenishing the media following serum starving. This 
demonstrates the importance of rigorous controls during cell culture experiments and 
studies which do show the correct positive and negative controls need to be viewed with 
caution. 
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CHAPTER FOUR 
 
The Role of G-CSF in Protein Synthesis and 
Protein Degradation of C2C12 Myotubes 
 
4.1 Introduction 
Healthy muscle mass is regulated by the continual synthesis and degradation of 
proteins. Decreased rates of protein synthesis and increased rates of protein degradation 
result in skeletal muscle atrophy, while the opposite is true of skeletal muscle 
hypertrophy. Skeletal muscle atrophy is a limiting factor for successful treatment and 
recovery in musculoskeletal disorders and many disease states. As such, skeletal muscle 
atrophy is a strong predictor of morbidity and mortality associated with cardiovascular, 
neuromuscular, musculoskeletal, nervous, renal and respiratory diseases and cancers 
[51, 61]. While resistance exercise is considered the most potent stimuli for muscle 
hypertrophy, prescribed exercise is not possible for many elderly individuals and those 
with chronic illnesses or injuries. Therefore, therapeutic agents targeting the molecular 
mechanisms regulating muscle mass need to be explored. 
 
Granulocyte-colony stimulating factor (G-CSF) is a cytokine that recently became of 
interest in the regulation of skeletal muscle mass. Rodents treated with G-CSF have 
increased skeletal muscle regeneration and force recovery following crush injury [136], 
while G-CSF facilitates skeletal muscle regeneration in rodents following a local 
cytotoxic injection [137]. Furthermore, SOD1tg mice, a rodent model of human ALS, 
have significantly improved muscle function following G-CSF treatment [223]. This is 
associated with a reduction in skeletal muscle loss, with SOD1tg mice having a 55 % 
larger muscle fibre diameter compared to non-treated animals. In G-CSFR knockout 
mice (G-CSFR-/-), fully grown animals are significantly smaller than their littermate 
counterparts, despite no postnatal abnormalities [138]. In particular, skeletal muscle 
diameter of the rectus femoris was significantly reduced. While these studies show that 
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G-CSF can affect skeletal muscle mass, it remains to be determined whether G-CSF 
regulates protein synthesis or protein degradation. 
 
G-CSF activates the intracellular signalling pathways Akt, STAT3 and Erk1/2 in cells 
expressing the G-CSFR [239, 319]. Akt increases skeletal muscle hypertrophy and 
attenuates skeletal muscle atrophy [244, 246-249]. The transcription factor STAT3 is 
rapidly phosphorylated and translocated to the nucleus in human skeletal muscle 
following resistance exercise [274] and is postulated to be involved in muscle 
adaptations to exercise. Erk1/2 is involved in fibre-specific protein accumulation in in 
rodents [369] and is increased following resistance and endurance exercise in an 
intensity dependant manner [277, 278, 370]. G-CSF treatment of C2C12 myoblasts 
significantly elevates Akt, STAT3 and Erk1/2 phosphorylation [138]. However it is 
currently unknown whether G-CSF activates Akt, STAT3 or Erk1/2 in skeletal muscle 
myotube cultures.  
 
The aim of this study was to determine whether G-CSF can increase protein synthesis 
and attenuate protein degradation in mouse C2C12 myotubes under basal and catabolic 
conditions. A secondary aim was to determine if G-CSF could activate Akt, STAT3 and 
Erk1/2 phosphorylation in C2C12 myotubes. 
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4.2 Methods 
4.2.1 Cell Culture 
C2C12 Myoblasts (American Type Culture Collection (ATCC), Manassas, VA) were 
maintained at 37 ºC with 5 % CO2, in high glucose Dulbecco's Modified Eagle's 
Medium (DMEM) supplemented with 10 % foetal bovine serum (FBS) (Invitrogen, 
Carlsbad, CA). When cells were confluent and showing signs of spontaneous fusion, 
myoblasts were serum depleted in high glucose DMEM supplemented with 2 % horse 
serum (Invitrogen) for 3-5 days to form myotubes.  
 
4.2.2 Protein Synthesis 
Protein synthesis was determined by measuring the incorporation of radio-labelled [3H]-
tyrosine into the myotubes (modified from [126]). C2C12 myotubes were treated for 24 
hours with or without 10 μM dexamethasone (DEX) (Sigma-Aldrich, St. Louis, MO) to 
induce catabolic stress, and with or without G-CSF at a concentration of 0, 0.4, 4, 40 
and 100 ng/ml. During this 24 hour period, 1 μCi/ml of radio-labelled [3H]-tyrosine and 
2 mM L-tyrosine (Sigma-Aldrich, St. Louis, MO) was added to the myotubes. After 24 
hours, myotubes were washed with ice cold PBS, followed by the addition of 1 ml of 
cold 10 % trichloroacetic acid (TCA) (Sigma-Aldrich, St. Louis, MO). The cells were 
removed from the cell culture dish by scraping and placed on ice for 1 hour, followed 
by centrifugation at 13,000 rpm for 10 minutes. The supernatant was removed, and the 
precipitate dissolved in 0.1 M NaOH with 1 % Triton X- 100 (TX-100) (Sigma-Aldrich, 
St. Louis, MO). radioactivity was measured using a Wallac 1409 DSA liquid 
scintillation counter (Perkin Elmer, Boston, MA) using Ultima Gold scintillation liquid 
(Perkin Elmer, Boston, MA). Radioactivity was expressed as counts per minute (CPM) 
and normalised to total genomic DNA content. Genomic DNA was extracted using the 
Allprep DNA/RNA mini kit (Qiagen, Melbourne, Australia) as per manufacturer’s 
instructions. DNA was quantified using the NanoDrop 2000 (NanoDrop products, 
Wilmington, DE).  
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4.2.3 Protein Degradation 
Protein degradation was determined by measuring the release of radio-labelled [3H]-
tyrosine from the myotubes into the media. C2C12 myotubes were incubated with 2 
μCi/ml of [3H]-tyrosine for 24 hours. Myotubes were washed in serum free high glucose 
DMEM and incubated in 2 mM L-tyrosine for 2 hours. After washing, myotubes were 
incubated in serum free DMEM with 2 mM unlabelled tyrosine with or without 10 μM 
DEX for 24 hours, to measure protein degradation under basal and catabolic conditions. 
Additionally myotubes were treated with or without G-CSF at 0, 0.4, 4, 40 and 100 
ng/ml during this time period. Following this, 450 μl of medium was added to 50 μl of 
TCA for 1 hour on ice. After centrifugation at 13,000 rpm for 5 minutes, radioactivity 
was measured (reading A) on the Wallac 1409 DSA liquid scintillation counter (Perkin 
Elmer, Boston, MA) using ultima Gold scintillation liquid. The remaining pellet was 
solubilised in 0.5 M NaOH with 0.1% Triton X-100 and the radioactivity was measured 
(reading B). The remaining myotubes were washed twice with cold PBS, followed by 
the addition of 0.5 M NaOH and 0.1% Triton X-100 for 2 hours at 37°C. Equal volumes 
of 10% TCA was added overnight at 4°C. The homogenate was removed and the 
radioactivity was measured (reading C). Proteolytic rate was defined as TCA-soluble 
radioactivity (reading A), divided by the total of reading A, B and C.  
 
4.2.4 Protein Extraction and Western Blotting 
G-CSF Treatment and Protein Extraction 
Myotubes were serum starved in DMEM (Invitrogen) for four hours followed by 
stimulation with serum free DMEM ± G-CSF. Total protein was extracted after 5, 10, 
15, 30 and 90 minutes and phosphorylation was compared to basal levels following four 
hours serum starvation. Protein was extracted using 1x radioimmunoprecipitation 
(RIPA) buffer (Millipore, North Ryde, NSW) with 1 μL/mL protease inhibitor cocktail 
(Sigma-Aldrich, Castle Hill, NSW) and 10 μL/mL Halt Phosphatase Inhibitor Single-
Use Cocktail (Thermo Scientific, Rockford, IL). Samples were centrifuged at 13,000 
rpm for 15 minutes with the protein concentration of the supernatant determined from 
the development of a standard curve using the bicinchoninic Protein Assay (BCA) Kit 
(Pierce Biotechnology, Rockford, IL) according to the manufacturer’s protocol.  
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Western Blotting 
Electrophoresis was performed using a 4-12 % NuPAGE® Novex Bis-Tris Gel 
(Invitrogen, Carlsbad, CA) in NuPAGE® SDS MOPS Running Buffer (Invitrogen, 
Carlsbad, CA). Proteins were transferred to a PVDF membrane (Millipore, North Ryde, 
NSW) in a Bjerrum buffer containing 50 mM Tris, 17 mM glycine and 10 % methanol. 
The membranes were blocked with 5 % BSA in PBS, after which they were incubated 
overnight at 4°C with the primary antibody diluted in 5 % BSA in PBS;  phospho-Akt 
(ser473), phospho-STAT3 (Tyr705), phospho-Erk1/2 (Thr202/Tyr204), Akt antibody, 
STAT3 antibody and Erk1/2 antibody (Cell Signalling Technology, Denvers, MA). 
Following washing, the membranes were incubated with the secondary antibody for 1 
hour which consisted of goat anti-rabbit IgG antibody (1:5000) labelled with an 
infrared-fluorescent 800 nm dye (Alexa Fluor® 800, Invitrogen) in PBS containing 50 
% Odyssey® blocking buffer (LI-COR Biosciences, Lincoln, NE) and 0.01 % SDS. 
Proteins were exposed on an Odyssey® Infrared Imaging System (LI-COR Biosciences, 
Lincoln, NE). After phospho protein exposure, the membranes were recovered and 
incubated in membrane stripping buffer (25 mM Glycine, 2 % w/v SDS; pH 2.0) three 
times for a total of 1 hour to remove the phospho antibody. Stripping efficiency was 
confirmed by incubation with the secondary antibody and protein exposure.  
  
4.2.5 Statistics 
Statistical analysis was performed using GraphPad Prism 4.1 (GraphPad Software, San 
Diego, CA). Means were compared using one-way repeated measures analysis of 
variance (ANOVA) for treatment (G-CSF or DEX) for protein degradation and 
synthesis, and for time (0, 5, 10, 15, 60, 90 minutes) for signalling proteins. Any 
differences between means were analysed using a Nueman-Keuls Post Hoc test. A 
probability level of p < 0.05 was adopted throughout to determine statistical 
significance unless otherwise stated. 
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4.3 Results 
4.3.1 Protein Synthesis 
DEX significantly reduced the rate of protein synthesis (Figure 4-01). G-CSF had no 
effect on the basal rates of protein synthesis at any concentration (Figure 4-01). At 0.4 
ng/ml G-CSF had no effect on the DEX-induced reduction in protein synthesis (Figure 
4-01A). G-CSF, at 4 ng/ml (Figure 4-01B) and 40 ng/ml (Figure 4-01C), attenuated the 
DEX-induced reduction in protein synthesis. However, at 100 ng/ml (Figure 4-01D), G-
CSF exacerbated the DEX-induced reduction in protein synthesis. 
 
 
Figure 4-01 The effect of G-CSF on protein synthesis under basal and catabolic conditions. 
Control (CTRL) and 10 μM Dexamethasone (DEX). (A) 0.4 ng/ml, (B) 4 ng/ml, (C) 40 ng/ml and 
(D) 100 ng/ml G-CSF. Data is Mean ± SD, n = 6, ** p < 0.01 when compared to CTRL.  * p < 0.05 
when comparing DEX to DEX + 100 ng/ml G-CSF.  
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4.3.2 Protein Degradation 
DEX significantly increased the rate of protein degradation (Figure 4-02). G-CSF had 
no effect at any concentration on the basal rates of protein degradation nor did G-CSF 
affect the DEX-induced increase in protein degradation (Figure 4-02). 
 
 
Figure 4-02 The effects of G-CSF on protein degradation under basal and catabolic 
conditions. Control (CTRL) and 10 μM Dexamethasone (DEX). (A) 0.4 ng/ml, (B) 4 ng/ml, (C) 40 
ng/ml and (D) 100 ng/ml G-CSF. Data is Mean ± SD, n = 6, * p < 0.05,  ** p < 0.01 and *** p < 
0.001 when compared to CTRL.   
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4.3.3 Protein Phosphorylation 
C2C12 myotubes were serum starved for four hours and protein was extracted from the 
control cells (time = 0 mins). Immediately prior to the start of the experiment, serum 
free DMEM + G-CSF was added to the cells and protein was extracted at 5, 10, 15, 30 
and 90 minute intervals.  
 
Akt Phosphorylation 
G-CSF treatment did not change Akt phosphorylation when compared to time 0 (Figure 
4-03A-D). However, Akt phosphorylation was significantly reduced at 90 minutes when 
compared to 10 minutes with 100 ng/ml G-CSF (Figure 4-03D). 
 
 
Figure 4-03 Akt phosphorylation levels in response to G-CSF treatment in C2C12 myotubes.  
The effects of G-CSF on Akt phosphorylation at 0, 5, 10, 15, 30 and 90 minutes with (A) 0.4 ng/ml, 
(B) 4 ng/ml, (C) 40 ng/ml and (D) 100 ng/ml G-CSF. Data is Mean ± SEM, n = 3. * p <0.05 
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STAT3 phosphorylation 
STAT3 phosphorylation was significantly reduced at 90 minutes independently of G-
CSF concentration (Figure 4-04A-D). At the highest concentration of G-CSF STAT3 
was significantly elevated 1.6-fold at 10 minutes (Figure 4-04D).  
 
 
 
Figure 4-04 STAT3 phosphorylation levels in response to G-CSF treatment in C2C12 
myotubes.  The effects of G-CSF on STAT3 phosphorylation at 0, 5, 10, 15, 30 and 90 minutes 
with (A) 0.4 ng/ml, (B) 4 ng/ml, (C) 40 ng/ml and (D) 100 ng/ml G-CSF. Data is Mean ± SEM, n = 
3, * p <0.05 when compared to the time zero (0) control.  
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ERK-1 phosphorylation 
Erk-1 phosphorylation was increased at 10 and 15 minutes irrespective of G-CSF 
concentration (Figure 4-05A-D). The greatest increase of 4.5-fold was observed with 40 
ng/ml G-CSF after 10 minutes. Erk-1 phosphorylation was back towards basal levels 
after 90 minutes in all treatment groups. 
 
 
Figure 4-05 Erk-1 phosphorylation levels in response to G-CSF treatment in C2C12 myotubes.  
The effects of G-CSF on Erk-1 phosphorylation at 0, 5, 10, 15, 30 and 90 minutes with (A) 0.4 
ng/ml, (B) 4 ng/ml, (C) 40 ng/ml and (D) 100 ng/ml G-CSF. Data is Mean ± SEM, n = 3, * p <0.05, 
when compared to the time zero (0) control. 
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ERK-2 phosphorylation 
Erk-2 phosphorylation was increased at 15 minutes irrespective of G-CSF concentration 
(Figure 4-06A-D). The greatest increase of 4-fold was observed with 100 ng/ml G-CSF 
after 10 minutes. Erk-1 phosphorylation was back towards basal levels after 90 minutes 
in all treatment groups. 
 
 
Figure 4-06 Erk-2 phosphorylation levels in response to G-CSF treatment in C2C12 myotubes.  
The effects of G-CSF on Erk-1 phosphorylation at 0, 5, 10, 15, 30 and 90 minutes with (A) 0.4 
ng/ml, (B) 4 ng/ml, (C) 40 ng/ml and (D) 100 ng/ml G-CSF. Data is Mean ± SEM, n = 3, * p <0.05, 
when compared to the time zero (0) control. 
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The Effects of Replenishing the Media on Akt, STAT3 and Erk1/2 Phosphorylation 
In Chapter 3 it was shown that Akt and Erk1/2 are responsive to the stress associated 
with changing media in C2C12 myoblasts. To determine if replenishing media influenced 
Akt, STAT3 and Erk1/2 phosphorylation in C2C12 myotubes, fresh serum free DMEM 
without G-CSF was added following four hours serum starving. Protein was extracted at 
5, 10, 15, 30 and 90 minutes following media replenishment and compared to time 0 
control. Akt phosphorylation did not change following media replenishment (Figure 4-
07A). STAT3 was significantly reduced at 90 minutes (Figure 4-08B). Erk-1 and Erk-2 
were both elevated at 10 minutes approximately 5-fold and 6.5-fold respectively (Figure 
4-08C and Figure 4-08D). 
 
Figure 4-07 The effects of changing media on Akt, STAT3 and ER1/2 phosphorylation C2C12 
myotubes. (A) Akt, (B) STAT3 (C) Erk-1 and (D) Erk-2 phosphorylation after replenishing the 
media. C2C12 myoblasts were 4 hour serum starved at time 0. Data is Mean ± SEM, n = 3, * p <0.05 
compared to time zero (0). 
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Vehicle vs G-CSF treatment on Akt and Erk phosphorylation 
It was of interest to differentiate between changes in phosphorylation caused by 
replenishing media with that of G-CSF treatment. To achieve this, media was 
replenished after 4 hours of serum starving with either fresh serum free DMEM without 
G-CSF (vehicle control) or with G-CSF (100 ng/ml). Akt phosphorylation did not 
change with vehicle or G-CSF treatment (Figure 4-08A). STAT3 was significantly 
elevated at 10 minutes and reduced at 90 minutes by both treatments (Figure 4-08B). 
Erk-1 and Erk-2 were both elevated at 10 minutes approximately 8-fold and 12-fold 
respectively, with no difference between vehicle and G-CSF treatment (Figure 4-08C 
and Figure 4-08D). 
 
Figure 4-08 Akt, STAT3 and Erk1/2 phosphorylation with 100 ng/ml G-CSF vs vehicle 
treatment. (A) Akt (B) STAT3 (C) Erk-1 and (C) Erk-2 phosphorylation treated with treated with 
vehicle control (white bars) or 100 ng/ml G-CSF (black bars) following serum starving. Data is 
Mean ± SEM, n = 3, * p <0.05 compared to time zero (0). 
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To confirm that G-CSF was not increasing Akt, STAT3 or Erk1/2 a spike in method 
was used. This method removes the confounding effects of the media change as C2C12 
myotubes are serum starved for four hours prior to 20 μl G-CSF being added to a final 
concentration of 100 ng/ml. Using this method G-CSF did not affect the 
phosphorylation of Akt, STAT3 or Erk1/2 (Figure 4-09).  
 
 
     
 
Figure 4-09 Akt, STAT3 and Erk1/2 phosphorylation with 100 ng/ml G-CSF in C2C12 
myotubes. Representative images of Akt, STAT3 and Erk1/2 phosphorylation following 
stimulation with G-CSF (40 ng/ml) from 5 – 90 minutes. 20 μl G-CSF was added to the media at 
time 0 minutes. Time zero represents four hours after serum free media was added to the cells. Ins 
= 100 μM insulin treated C2C12 myotubes 15 minutes using the spike in method. 
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4.4 Discussion 
G-CSF treatment leads to higher muscle protein content in mice following crush injury 
[136] and an improved motor function and 55 % larger muscle fibres in ALS mice 
[223]. Therefore, this study aimed to determine if G-CSF treatment influenced protein 
turnover in C2C12 myotubes under basal and catabolic conditions induced by DEX. In 
chapter 2 the G-CSFR was identified in C2C12 myotubes. Therefore, it was of interest to 
see if G-CSF could stimulate intracellular signalling pathways associated with the G-
CSFR. Several novel observations were made. Firstly, G-CSF treatment did not 
influence protein synthesis under basal conditions. Secondly, G-CSF treatment 
attenuated the DEX induced reduction in protein synthesis at 4 and 40 ng/ml. At a 
higher dose of 100 ng/ml, G-CSF exacerbated the DEX-induced reduction in protein 
synthesis. Thirdly, G-CSF treatment did not influence protein degradation under normal 
or catabolic conditions. Lastly, G-CSF did not increase phosphorylation of Akt, STAT3 
or Erk1/2 in C2C12 myotubes. 
 
Myofibres are incapable of mitotic division and therefore rely on post mitotic regulation 
of protein turnover to regulate growth [2]. In the current study, G-CSF treatment had no 
effect on basal protein synthesis or protein degradation in C2C12 myotubes, but did 
affect protein synthesis in combination with DEX treatment. DEX is a glucocorticoid 
that inhibits protein synthesis and induces protein degradation in C2C12 myotubes, 
creating a catabolic environment [371]. In the current study DEX decreased protein 
synthesis by 13 % and increased protein degradation by 14 %. At 4 ng/ml and 40 ng/ml, 
G-CSF treatment attenuated the decline in protein synthesis seen with DEX treatment. 
However, at a much higher dose of 100 ng/ml, G-CSF exacerbated the effects of DEX, 
further decreasing protein synthesis to 18 %. Similar evidence exists for other type 1 
cytokines such as TNFα. For example, in C2C12 cells, a 40 % decrease in protein 
synthesis is observed with 50 ng/ml TNFα [125], while at 10 ng/ml an increase in 
protein synthesis is observed [126]. The results from this study suggests that G-CSF 
treatment may regulate muscle mass by modulating protein synthesis under catabolic 
conditions in which glucocorticoid hormones are elevated. Physiologically, G-CSF 
never reaches more than 3-4 ng/ml during extreme sepsis [345]. Following G-CSF 
treatment patients reach peak levels in 2-8 hours, usually not exceeding 40-50 ng/ml 
[170]. In rodents, G-CSF treatment is associated with higher muscle protein content, 
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improved motor function and larger myofibre diameter in injured and diseased skeletal 
muscle [136, 223].  This suggests G-CSF treatment may attenuate a reduction in protein 
synthesis caused by a catabolic environment and contribute to the increased recovery 
observed following injury and/or disease. 
 
Parallel to the results obtained in chapter 3, G-CSF did not increase Akt, STAT3 or 
Erk1/2 phosphorylation in C2C12 myotubes above that of the vehicle control. This is 
despite the G-CSFR being identified on terminally differentiated C2C12 myotubes in 
chapter 2. Analogous to this, Macrophage-Colony Stimulating Factor (M-CSF), a close 
relative of G-CSF, is implicated as a regulator of skeletal muscle in similar ways to G-
CSF in vivo [372]. Despite the M-CSF receptor being present on mature skeletal muscle 
[372], M-CSF does not directly influence C2C12 myotube cultures [373]. The observed 
attenuation of DEX induced reduction in protein synthesis may have been independent 
of these signalling pathways. In LPS treated C2C12 myotubes an increase in Akt 
phosphorylation is observed [374]. This presumably down-regulates the UPP pathway, 
decreasing protein degradation; however atrophy of the myotubes still occurs. 
Therefore, since G-CSF treatment had no effect of basal levels of protein synthesis or 
protein degradation an increase in Akt, STAT3 or Erk1/2 may not have been expected. 
Under catabolic conditions an increase in these signalling proteins may be observed in 
response to G-CSF treatment, this remains to be determined.  
 
In conclusion, G-CSF treatment of C2C12 myotubes attenuates a reduction in protein 
synthesis during DEX induced catabolism at physiological doses, and exacerbates the 
DEX induced reduction in protein synthesis at high doses. Therefore, G-CSF may 
protect skeletal muscle during catabolic conditions leading to an increase in muscle 
mass and muscle function. However, the molecular mechanisms regulating this 
response remain to be determined. 
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CHAPTER FIVE 
 
Role and Regulation of G-CSF in Inflammation 
 
5.1 Introduction 
Following skeletal muscle damage, inflammation is an important process necessary for 
muscle repair [375]. Pro-inflammatory cytokines initiate an inflammatory response, 
recruiting neutrophils and macrophages to the injury site, which aids in clearing 
damaged tissue [109]. Anti-inflammatory cytokines released at the injury site modulate 
the inflammatory response and aim to control the pro-inflammatory cytokine release 
[376]. Pro-inflammatory cytokines and infiltrating neutrophils activate reactive oxygen 
species (ROS)-generating enzymes that have been linked to secondary muscle damage 
[79, 377]. However ROS and pro-inflammatory cytokines appear to play a vital role in 
muscle repair through the activation of myogenesis and protein turnover in skeletal 
muscle [378]. The most commonly used drugs to treat inflammation and associated pain 
are non-steroidal anti-inflammatory drugs (NSAIDS), such as ibuprofen. However, 
NSAIDS are known for their ability to scavenge ROS [379-381] and reduce 
macrophage recruitment [89, 382], and consequently reduce the long term regeneration 
of skeletal muscle following injury [14, 382-384]. Therefore, understanding and 
modulating the inflammatory response has become a vital research area associated with 
sport and disease, with the overall focus on increasing muscle recovery and long term 
muscle function.  
 
G-CSF has emerged as a potential therapeutic agent to improve muscle regeneration and 
force recovery post trauma [319]. G-CSF elicits a biological function by binding to its 
own receptor the G-CSF receptor (G-CSFR) [319]. The administration of G-CSF 
enhances muscle strength and recovery following crush injury of the hind limb in 
rodents, [136] reduces the time of muscle regeneration following cardiotoxin injection 
and increases cellular infiltration into the damaged tissue [137]. G-CSF treatment 
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protects rodents against LPS induced toxicity, a model of sepsis, via suppression of 
TNFα [310]. Muscle cells release IL-6, TGF-β, GM-CSF, IL-1α, IL-1β TNFα, IL-8 and 
MCP-1 either constitutively or when stimulated with a variety of pro-inflammatory 
cytokines [108, 119]. Cultured human myotubes also release pro-inflammatory 
cytokines IL-1, -2, -5, -7, -10, -12, -13, -17 and GM-CSF at basal levels, and release of 
IL-8, GM-CSF, G-CSF, MCP-1, and IL-6 in response to stretch-induced damage [116]. 
However fibroblasts routinely contaminate primary skeletal muscle cultures [385] are 
known to produce G-CSF [386]. Therefore it remained undetermined if muscle 
produces G-CSF. However, the release of G-CSF may be an attempt to attenuate the 
inflammatory-induced damage. In support of this, G-CSF treatment attenuates the LPS-
induced inflammatory response in whole blood ex vivo [311]. Whether G-CSF is 
released from, or if G-CSF treatment modulates the inflammatory response in cultured 
skeletal muscle myotubes is unknown. 
 
Eccentric exercise is known to cause myofibre damage coupled with rapid muscular 
adaptations to prevent further injury upon repeated bouts of exercise [387, 388]. 
Contraction-induced inflammation has long been implicated as deleterious to skeletal 
muscle, causing secondary muscle damage caused by reactive oxygen species (ROS) 
[111, 312, 377]. Supplementation with antioxidants and anti-inflammatory agents such 
as N-Acetyl Cysteine (NAC) [315] inhibits fatigue and blunts a reduction in muscle 
force production 24 and 48 hours post eccentric exercise, however long term muscle 
function is hampered [317]. This observation supports emerging evidence that ROS 
production is essential for the adaptive changes to exercise [389]. G-CSF is increased in 
circulation following damaging exercise [115, 313, 390] and in Chapter 2 it was 
observed that the G-CSFR mRNA is increased in skeletal and diaphragm muscle of the 
mdx mouse. Therefore the release of G-CSF by skeletal muscle following inflammatory 
stress may be an attempt to aid muscle repair [106, 120, 121] via an autocrine loop.  In 
vitro, anti-inflammatory treatment with NAC inhibits the G-CSF [316] stimulation of 
ROS and proliferation in BAF/3 cells [314]; proliferation being an initial key step in 
muscle repair. Therefore NAC administration may attenuate G-CSF levels in circulation 
and muscle following eccentric exercise. Whether G-CSFR is altered in healthy skeletal 
muscle following acute muscle damage has not been investigated.   
 
As the role and regulation of G-CSF and the G-CSFR in skeletal muscle inflammation 
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is not precisely understood, the aims of this study were to firstly, determine if G-CSF is 
regulated using two models of inflammation; 1) LPS treatement of C2C12 myotubes and 
2) eccentric-damaging exercise. A second aim was to determine if G-CSF treatment 
blunts the inflammatory response induced by LPS in C2C12 myotubes. The third aim of 
this study was to determine if the G-CSFR is modulated following eccentric-damaging 
exercise and finally; establish if supplementation with NAC reduces G-CSF production 
and modulates the G-CSFR following eccentric-damaging exercise. 
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5.2 Methods 
5.2.1 Cell Culture  
C2C12 myoblasts (ATCC) were seeded at a density of  4 x 104  cell/ml into six well cell 
culture plates and incubated at 37ºC, 5% CO2 in growth media consisting of high 
glucose Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% foetal 
bovine serum (Invitrogen, Carlsbad, CA). Once cells became confluent and showed 
signs of spontaneous differentiation, high glucose DMEM supplemented with 2% horse 
serum (HS) (Invitrogen) replaced the growth media for five days. Growth and 
differentiation media was replaced every 48 hours throughout the experiments unless 
stated otherwise.  
 
LPS treatment 
At the beginning of the experiment the cell culture media was removed and replaced 
with serum free DMEM containing the vehicle, 1 μg/ml LPS (E.Coli 0111:B4) (Sigma-
Aldrich, Sydney, Australia) to induce an inflammatory response [391], 100 ng/ml G-
CSF or the combination of LPS and G-CSF. After one, two, four and 24 hours, cell 
culture media was removed, immediately snap frozen in liquid nitrogen and stored at -
80 °C for cytokine analysis. The cell layer was washed in ice cold PBS and harvested 
for RNA extraction. 
 
5.2.2 Eccentric Exercise and NAC Trial 
Study Design 
Muscle and plasma samples were a generous gift obtained from a larger study [317]. 
For detailed methods see Appendix 1. In brief, ten healthy male volunteers participated 
in this study.  Participants were non-smokers, recreationally trained and had been 
engaged in regular exercise at least three times/week for more than 12 months. The 
study design was a double-blind, cross-over, repeated-measures study (Figure 3-01), 
where subjects received either NAC or placebo supplementation immediately following, 
and daily for eight days post-exercise.  The trial was performed in a random order with 
a six week washout period between trials. Muscle and blood samples were collected 
pre-exercise, two hours, 48 hours and eight days post-exercise. Subjects characteristics 
prior to each trial are seen in table 5-02. 
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Exercise Protocol 
Acute leg eccentric exercise was performed on an Isoforce (TUR Gmbh, Berlin, 
Germany) isokinetic dynamometer with participants performing 300 unilateral 
repetitions consisting of 15 repetitions/set with 30 seconds rest between sets (Figure 3-
01). This protocol has previously been shown to induce myofibrillar disruption when 
exercise is controlled at 30°/second [392]. 
 
Supplementation 
Subjects ingested a NAC or placebo (PLA) solution orally in 3 daily doses. The 
solutions consisted of 375 ml water, 125 ml sugar free cordial and two grams low 
calorie glucose/dextrose powder. During the NAC trial an additional 20 mg.kg-1.day-1 
NAC (Uni-Pharma) was diluted in the solution. Blinded pilot trials confirmed no 
difference in palatability between the two drinks.  
 
Sample Preperation 
Muscle samples were homogenized in ice-cold extraction buffer (50 mM Tris-HCL, pH 
7.5, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% triton-X, 50 mM sodium fluoride, 5 
mM sodium pyrophosphate, 1 mM dithiothreitol, 10 μg/mL trypsin inhibitor, 2 μg/mL 
aprotinin, 1 mM benzamidine and 1 mM phenylmethylsulfonyl fluoride). The lysate 
was centrifuged (12,000g, 20 minutes, 4 °C) and protein concentrations of the 
supernatants were determined from the development of a standard curve using the 
bicinchoninic Protein Assay (BCA) Kit (Pierce Biotechnology, Rockford, IL) according 
to the manufacturer’s protocol. Muscle lysates were diluted to 1 μg/ml for cytokine 
analysis. 
 
Blood samples (15 mL) were drawn from the antecubital fossa using a 20-gauge 
disposable needle equipped with a Vacutainer tube holder (Becton Dickinson, Franklin 
Lakes, NJ) in a seated position at 7:00 a.m. following an overnight fast. A portion of the 
blood was collected in tubes with EDTA, centrifuged (1370g, 10 minutes at 4 oC), and 
the plasma collected. 
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Figure 5-01 Eccentric exercise with NAC supplementation repeated measures study design 
[317].  
 
 
Table 5-01 Subject characteristics prior to each trial 
Placebo trial NAC trial 
Age (years) 23.5 ± 2.5 23.5 ± 2.5 
Body mass (kg) 76.3 ± 9.0 76.0 ± 9.7 
Lean body mass (kg) 65.2 ± 7.0 65.1 ± 7.3 
Height (m) 1.77 ± 0.10 1.77 ± 0.10 
BMI (kg/m2) 24.4 ± 2.2 24.3 ± 2.2 
Body Fat (%) 14.3 ± 3.5 14.2 ± 3.2 
VO2max (ml.min-1.kg-1) 47.7 ± 4.6 47.5 ± 4.4 
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5.2.3 Messenger RNA (mRNA) Expression 
RNA was isolated using TRI-Reagent® (Ambion Inc., Austin TX) according to the 
manufacturer’s protocol. RNA concentration was determined by the absorbance at a 
wavelength of 260 nm using the NanoDrop® ND-1000 spectrophotometer (NanoDrop 
products, Wilmington, DE). RNA (1.0 μg) was treated with DNAse amplification grade 
I (Invitrogen) before being reverse transcribed to synthesise first strand cDNA using the 
high-capacity RNA-cDNA reverse transcription kit (Applied Biosystems, Forster City, 
CA). All cDNA was diluted to a working concentration of approximately 5 ng/μl.  
 
Real-time polymerase chain reaction (RT-PCR) was used to measure mRNA 
expression. The primers for the genes of interest, G-CSF, IL-4, IL-6, IL-10, IL-12, IL-
18, MCP-1 and TNFα were designed using the web based software Primer 3 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Sequences were designed 
and checked across exons using the Ensemble Genome Project (www.ensembl.org). The 
sequences were cross checked for gene specificity using a BLAST search 
(www.ncbi.nlm.gov/BLAST). Primers were synthesised by GeneWorks (Adelaide, SA). 
PCR primer details for the mouse genes are provided in Table 2-01. RT-PCR was 
performed using a Stratagene Mx3000p QPCR (Stratagene, La Jolla CA) with SYBR 
Green PCR Mastermix (Applied Biosystems). Each reaction contained 25 ng cDNA and 
0.2 μM of each forward and reverse primer. The thermal profile consisted of denaturing 
of 95 °C for 10 min, followed by 40 cycles of 95 °C for 30 seconds, 60 °C for 60 
seconds, and 72 °C for 30 seconds. Samples were normalised to the house-keeping gene 
36B4.  
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Table 5-02 Mouse primer sequences for RT-PCR. 
Gene 
GeneBank 
Accession no. Forward 5’ – 3’ Reverse 5’ – 3’ 
G-CSF NM_009971 CGT TCC CCT GGT CAG TGT C CCG CTG GCC TGG ATC TTC 
IL-4 NM_021283 TCA ACC CCC AGC TAG TTG TC TGT TCT TCG TTG CTG TGA GG 
IL-6 NM_031168 CCG GAG AGG AGA CTT CAC AG CAG AAT TGC CAT TGC ACA AC 
IL-10 NM_010548 CCA AGC CTT ATC GGA AAT GA TTT TCA CAG GGG AGA AAT CG 
IL-12β NM_008352 AGG TCA CAC TGG ACC AAA GG TGG TTT GAT GAT GTC CCT GA 
IL-18 NM_008360 ACA ACT TTG GCC GAC TTC AC GGG TTC ACT GGC ACT TTG AT 
MCP-1 NM_011311 CCC AAT GAG TAG GCT GGA GA TCT GGA CCC ATT CCT TCT TG 
TNFα NM_013693 CCC CAA AGG GAT GAG AAG TT GGT CTG GGC CAT AGA ACT GA 
36B4 NM_007475 TTG TGG GAG CAG ACA ATG TG AGT CCT CCT TGG TGA ACA CG 
 
 
5.2.4 Western Blotting 
Electrophoresis was performed using a 4-12 % NuPAGE® Novex Bis-Tris Gel 
(Invitrogen, Carlsbad, CA) in NuPAGE® SDS MOPS Running Buffer (Invitrogen, 
Carlsbad, CA). Proteins were transferred to a PVDF membrane (Millipore, North Ryde, 
NSW) in a Bjerrum buffer containing 50 mM Tris, 17 mM glycine and 10 % methanol. 
The membranes were blocked with 5 % BSA in PBS, after which they were incubated 
overnight at 4 °C with anti-G-CSFR antibody (Santa Cruz) diluted in 5 % BSA in PBS. 
Following washing, the membranes were incubated for 1 hour with goat anti-rabbit IgG 
antibody (1:5000) labelled with an infrared-fluorescent 800 nm dye (Alexa Fluor® 800, 
Invitrogen, Carlsbad, CA) in PBS containing 50 % Odyssey® blocking buffer (LI-COR 
Biosciences, Lincoln, NE) and 0.01 % SDS. Proteins were exposed on an Odyssey® 
Infrared Imaging System (LI-COR Biosciences, Lincoln, NE) and densitometry was 
achieved using Odyssey Application Software 3.0 (LI-COR Biosciences Lincoln, NE). 
GAPDH (1:5000) (G8795, Sigma-Aldrich, Sydney, Australia) and rabbit anti-mouse 
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IgG antibody labelled with an infrared-fluorescent 680 nm dye (Alexa Fluor® 680, 
Invitrogen) was used as a loading control.  
 
5.2.3 Cytokine Analysis 
A Milli-plex assay (Millipore, Billerica, MA) was used to analyse the cytokine 
expression in the cell culture media, plasma and muscle lysates. The cytokine detection 
kits were designed for the simultaneous analysis of multiple cytokines, G-CSF, TNFα, 
IL-6 and MCP-1, for the cell culture experiments and a single-plex for G-CSF for 
plasma and muscle lysates. The assays were conducted following the manufacturer’s 
protocol (Millipore, Billerica, MA). Briefly, a standard curve was serial diluted using 
the supplied standard with a range of 10,000 pg/ml – 0.64 pg/ml. Then, 25 μl of samples 
and standards were added to a 96 well plate containing the premixed beads coated with 
the target antibody. Following an overnight incubation, plates were washed twice in 
wash buffer, and 25 μl of pre-mixed detection antibodies were added and allowed to 
incubate. After 60 minutes, 25 μl of streptoavidin-phycoerythrin was added to each well 
and allowed to incubate for a further 30 minutes. After incubating, wells were washed 
two times in wash buffer and resuspended in 150 μl of sheath fluid. The plate was then 
analysed on the Bio-Plex Suspension Array System (V.5.0, Bio-Rad) using the 5-PL 
curve. Samples were run in duplicate, using the low sensitivity (low PMT) function. For 
the cell culture media intra-assay coefficient of variations (CV%) were as follows; G-
CSF: 4.7 %, IL-6: 3.5 % and MCP-1: 5.5 %. For the NAC trial CV% were; Plasma G-
CSF 3.2 %; muscle lysates G-CSF 7.9 %. 
 
5.2.4 Statistical Analysis 
Cell culture 
Statistical analysis was performed using GraphPad Prism 4.1 (GraphPad Software, San 
Diego, CA). Means were compared using one-way repeated measures analysis of 
variance (ANOVA) comparing treatment for each time point, Any significant 
differences were analysed using a Newman-Keuls Post Hoc test. Data is presented as 
Mean ± standard error of the mean (SEM). Significance was set at p < 0.05. 
 
NAC Eccentric-Damaging Exercise 
Changes in dependent variables were examined with a 2-factor, repeated measures 
ANOVA [trial( PLA and NAC) x time (Pre, 2 hours post, 2 days post, 48 hours post 
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exercise) using SPSS version 21 (SPSS Inc.). Significance was set p < 0.05. When a 
significant interaction was detected, post hoc analysis was performed through the 
Bonferonni adjustment.  
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5.3 Results 
5.3.1 Messenger RNA (mRNA) Expression 
LPS stimulation significantly increased the mRNA expression of G-CSF approximately 
4-fold and 17-fold above the control group at 1 and 2 hours, respectively, while 
returning to baseline at 4 and 24 hours. G-CSF treatment had no effect on G-CSF 
mRNA levels nor did G-CSF treatment affect the LPS-stimulated elevation of G-CSF 
mRNA at any time point (Figure 5-02A).  
IL-6 mRNA was significantly elevated by LPS, peaking at approximately 110-fold 
above that of the control group at 4 hours. G-CSF had no effect on baseline IL-6 mRNA 
expression at any time point. However, IL-6 mRNA was significantly elevated above 
the LPS treated group with the addition of 100 ng/ml G-CSF at 1, 2 and 4 hours. The 
greatest increase was at 4 hours which was 1.6-fold greater than the LPS group alone. 
At 24 hours IL-6 mRNA expression had returned to baseline in the LPS group and the 
LPS + G-CSF treated group (Figure 5-02B).  
Both TNFα (Figure 5-02C) and MCP-1 (Figure 5-02D) were significantly elevated 
above the control group by LPS treatment at one, two, four and 24 hours. At 4 hours 
mRNA expression of TNFα was approximately 63-fold and MCP-1 was approximately 
495 fold compared to the control group. G-CSF had no effect on basal or LPS-
stimulated TNFα and MCP-1 mRNA expression. 
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Figure 5-02 mRNA expression of G-CSF, TNFa, IL-6 and MCP-1 in C2C12 myotubes following 
LPS and G-CSF stimulation. (A) G-CSF (B) IL-6 (C) TNFα and (D) MCP-1 mRNA expression at 
1, 2, 4 and 24 hours following 1 μg/ml LPS stimulation with and without the addition of 100 ng/ml 
G-CSF. Data is fold change above time zero, n = 3 in two repeated experiments. Data is Mean ± 
SEM, ** p <0.01, when compared to control at the same time point.  # p <0.05 when compared to 
LPS at the same time point. 
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LPS treatment had no effect on the mRNA expression of IL-4, IL-10, IL-12B or IL-18 
at 1, 2, 4 or 24 hours. Similarly G-CSF treatment had no effect on the expression of 
these cytokines nor did the combined treatment of LPS and G-CSF (Figure 5-03). 
 
 
Figure 5-03 mRNA expression of IL-4, IL-10, IL-12β and IL-18 in C2C12 myotubes following 
LPS and G-CSF stimulation. (A) IL-4 (B) IL-10 (C) IL-12β and (D) IL-18 mRNA expression at 1, 
2, 4 and 24 hours following 1 μg/ml LPS stimulation with and without the addition of 100 ng/ml G-
CSF. Data is Mean ± SEM, n = 3. 
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5.3.2 Cytokine Analysis 
G-CSF 
In cell culture media, G-CSF was below the detectable levels (<DL) of the assay in the 
control group throughout the experiment (Table 5-03). Following LPS treatment, G-
CSF was detectable at 2 hours and remained detectable at 4 and 24 hours (Table 5-03). 
The highest concentration of G-CSF following LPS stimulation was 144 pg/ml at 4 
hours. In the G-CSF and G-CSF+LPS groups, G-CSF concentration was <DL of the 
assay (data not shown). 
 
Table 5-03 G-CSF concentration (pg/ml) in cell culture media following LPS stimulation of 
C2C12 myotubes 
Treatment T0 1 Hour 2 Hours 4 Hours 24 Hours 
Vehicle Control <DL <DL <DL  <DL <DL 
1 μg/ml LPS --- <DL 23 ± 2 144 ± 7 120 ± 4 
T0 = time zero control, <DL below detectable limits, Data is Mean ± SEM, n =6 
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IL-6 
LPS stimulation significantly increased the concentration of IL-6 in cell culture media 
at 1, 2, 4 and 24 hours when compared to the same time point controls (Table 5-04). At 
each time point G-CSF had no effect on IL-6 concentrations. At 24 hours the LPS 
stimulated IL-6 concentration was 6682 ± 310 pg/ml, while the addition of G-CSF to 
the LPS treatment significantly increased the concentration of IL-6 to 8811 ± 328 pg/ml 
within the media (Table 5-04). There was no effect of G-CSF on the LPS-stimulated 
increase in IL-6 at 1, 2 or 4 hours. 
 
Table 5-04 IL-6 cytokine concentration (pg/ml) in the cell culture media following LPS and G-
CSF stimulation of C2C12 myotubes 
Treatment 1 Hour 2 Hours 4 Hours 24 Hours 
Vehicle Control 18 ± 2 110 ± 17 116 ± 10 106 ± 9 
1 μg/ml LPS 37 ± 5* 1190 ± 58*** 4757 ± 440*** 6682 ± 310*** 
100 ng/ml G-CSF 10 ± 2 77 ± 7 100 ± 9 105 ± 9.2 
1 μg/ml LPS + 
100 ng/ml G-CSF 
36 ± 6* 1236 ± 79*** 5610 ± 518*** 8811 ± 328***† 
Data is Mean ± SEM, n=6, *p<0.05, ***p<0.001 compared to control at same time point. †p<0.001 
compared to 1 μg/ml LPS at the same time point. 
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MCP-1 
The concentration of MCP-1 was not detectable at baseline or after 1 hour with LPS or 
G-CSF treatment (Table 5-05). At 2 hours the concentration of MCP-1 was 730 ± 66 
and 842 ± 66 pg/ml in the LPS and LPS + G-CSF, respectively, with no difference 
between the groups. MCP-1 remained <DL in the control and G-CSF groups. After 4 
hours, MCP-1 was detectable at low levels in the control group, while LPS treatment 
significantly elevated MCP-1. G-CSF treatment had no effect on basal levels of MCP-1 
or the increase in MCP-1 stimulated by LPS (table 5-05).  At 24 hours LPS significantly 
increased the concentration of MCP-1 above that of the control group. Again the 
addition of G-CSF had no effect on basal levels of MCP-1 or the increase in MCP-1 
stimulated by LPS 
 
Table 5-05 MCP-1 cytokine concentration (pg/ml) in cell culture media following LPS and G-
CSF stimulation of C2C12 myotubes  
Treatment 1 Hour 2 Hours 4 Hours 24 Hours 
Vehicle Control <DL <DL 23 ± 0 108 ± 3 
1 μg/ml LPS <DL 730 ± 66 3683 ± 63*** 8654 ± 172*** 
100 ng/ml G-CSF <DL <DL 23 ± 2 86 ± 2 
1 μg/ml LPS + 
100 ng/ml G-CSF 
<DL 842 ± 66 3650 ± 99*** 8767 ± 210*** 
Data is Mean ± SEM, n=6, ***p<0.001 compared to control at same time point.  
 
TNFα  
The concentration of TNFα was <DL at all-time points using the cytokine assay. The 
average fit probability for the TNFα standard curve was 0.94 and the quality control 
samples (supplied with the kit) were within the correct range (data not shown). 
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5.3.3 Eccentric Exercise and NAC Supplementation Results 
Muscle Function 
These results are from previously published data [317] and were not collected as part of 
this PhD thesis. The full results can be viewed in appendix 3. In brief, mean torque 
decreased through the eccentric exercise protocol with no differences between groups. 
During recovery, mean torque was at its lowest 48 hours post exercise in both the PLA 
and NAC trials. Mean torque was significantly higher in the NAC trial at 24 and 48 
hours post exercise. However, after eight days the opposite was observed where mean 
torque in the PLA group was significantly higher than the NAC trial. 
 
Inflammatory markers 
These results are from previously published data [317] and were not collected as part of 
this PhD thesis. The full results can be viewed in appendix 3.  In brief, creatine kinase 
(CK), C-reactive protein (CRP), macrophage infiltration and circulating neutrophils 
increased in both the trials. NAC resulted in an attenuation of CK and CRP at 48 hours 
and an attenuation of circulating neutrophils at two hours. The circulating cytokine 
levels of IL-1β and IL-6 were elevated at two hours and 48 hours compared to pre 
exercise levels in both trials. After eight days IL-10 was significantly elevated in both 
trials. NAC supplementation significantly blunted the IL-1β and IL-6, but resulted in a 
significantly higher IL-10 concentration compared to the PLA trial. 
 
The muscle function tests and changes in inflammatory markers obtained from this 
study have briefly been mentioned to demonstrate the effectiveness of the exercise 
protocol to induce muscle damage and cause an inflammatory response. This is evident 
by the marked elevation of CK, CRP, proinflammatory cytokines, leukocytosis and a 
substantial decrease in muscle function. 
 
G-CSF Expression Following Eccentric Exercise and NAC Supplementation 
Plasma concentrations of G-CSF for one subject were determined to be significant 
outliers using the extreme studentised deviate (ESD) method (GraphPad Software, San 
Diego, CA) prior to exercise in both trials. Subsequently this subject was removed from 
the analysis. 
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Two way repeated measures ANOVA revealed a significant main effect for time (p = 
0.015) on G-CSF plasma levels. Post Hoc analysis revealed there was a significant 
elevation in G-CSF levels at 2 hours post exercise compared to pre-exercise (Figure 5-
04). There was no main effect for treatment (PLA vs NAC). There was no main effect 
for time or treatment for the G-CSF concentration in skeletal muscle lysates. 
 
 
Figure 5-04 Plasma and skeletal muscle G-CSF levels following eccentric damaging exercise 
and NAC supplementation. (A) G-CSF levels (pg/ml) in Plasma and (B) G-CSF levels (pg/ug 
protein) in muscle homogenates. Subjects received a placebo or NAC 20 mg.kg-1.day-1 supplement 
for 8 days post-exercise. Exercise consisted of 300 acute leg eccentric contractions on an Isoforce 
(TUR Gmbh, Berlin, Germany) dynamometer in a repeated measures cross over study. Data is 
Mean ± SEM, n = 10, * p <0.05 compared to pre exercise levels. 
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G-CSFR Expression Following Eccentric Exercise and NAC Supplementation 
There was no change in G-CSFR expression in the muscle homogenates following 
eccentric damaging exercise or NAC supplementation (Figure 5-05). The glycosylated 
G-CSFR bands were not detected by western blotting in these subjects (data not shown). 
 
 
Figure 5-05 G-CSFR expression in skeletal muscle homogenates following Eccentric damaging 
Exercise and NAC supplementation. (A) Representative western blot image from one subject (B) 
Densitometry analysis of the 85kDa G-CSFR band. Data is Mean ± SEM, n = 10.  
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5.4 Discussion 
Following skeletal muscle damage, G-CSF is increased in circulation [115, 313, 390]. 
Furthermore, skeletal muscle has been identified as a source of cytokine production [84, 
393, 394]. This suggests that G-CSF may be produced by muscle following an 
inflammatory stimulus. Firstly, it was of interest to determine if G-CSF was increased 
from muscle using two models of inflammation; 1) LPS treatment of C2C12 myotubes in 
vitro and 2) eccentric-damaging exercise in humans. It was interest to determine if G-
CSF treatment blunts the inflammatory response in vitro. Thirdly, it was of interest to 
determine if the G-CSFR is modulated following eccentric damaging exercise and 
finally if NAC supplementation blunts the G-CSF and G-CSFR response following 
eccentric-damaging exercise. Several novel observations were made. In vitro LPS 
stimulates the release of G-CSF from C2C12 myotubes. In vivo, after eccentric-damaging 
exercise G-CSF is elevated in circulation but not in the muscle tissue. G-CSF increased 
the IL-6 response following LPS stimulated inflammation in C2C12 myotubes, while 
NAC had no effect on G-CSF or the G-CSFR in vivo.  
 
This study shows for the first time that G-CSF is released from muscle myotubes in 
response to an inflammatory stimulus. Findings from the current study therefore suggest 
that G-CSF may act as a myokine during inflammation. LPS treatment is used to 
simulate the effects of sepsis in cell culture models and rodent studies in vivo [395]. 
Sepsis is associated with an increase in skeletal muscle atrophy and inflammation [396-
398]. During sepsis an early increase in circulating G-CSF is associated with survival 
[399], while G-CSF treatment increases survival in this model [400].  In a second model 
of inflammation, circulating G-CSF levels were elevated by 40 % post eccentric-
damaging exercise. This is analogous to previous studies that show increased plasma G-
CSF of approximately 20 % after one hour and 70 % after six hours post eccentric-
damaging exercise [115]. This study shows for the first time that the increase in 
circulating G-CSF does not correlate with an increase in muscle tissue G-CSF. The 
significance of the elevated G-CSF following LPS induced inflammation remains to be 
determined however these results suggest that the G-CSF response may be specific to 
the inflammatory stimuli.    
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In the current study LPS stimulation significantly increased IL-6 and TNFα mRNA in 
C2C12 myotubes, while G-CSF further enhanced LPS induced IL-6 production. The role 
of IL-6 in skeletal muscle is not clearly understood. IL-6 knockout rodent myoblasts 
display a reduced proliferation rate in vitro [129]. During exercise a consistent finding 
is that IL-6 is increased, and the majority of IL-6 production is muscle derived [401]. 
Genetic loss of IL-6 results in a reduced hypertrophic response to functional 
overloading in rodent muscle [129], showing that IL-6 is required for the hypertrophic 
responses to resistance exercise possibly by controlling the inflammatory response. The 
increase in IL-6 precedes anti-inflammatory cytokine expression [402] and IL-6 inhibits 
pro-inflammatory cytokines such as TNFα during exercise [403]. Thus, acutely, IL-6 is 
beneficial to muscle growth and hypertrophy but chronically elevate or high dose IL-6 
produces muscle atrophy [130]. Sepsis however, produces a different inflammatory 
profile. Increases in TNFα are rarely seen during exercise, but precede the increase in 
IL-6 during sepsis [404] with TNFα/IL-6 considered causal to sepsis induced protein 
loss [405]. G-CSF prevents death by LPS induced toxicity in rodents [310]. In rodents, 
TNFα, IL-6, IL-8 and IL-1ra are elevated when G-CSF is administered immediately 
prior to LPS, however G-CSF administered 24 hours prior to LPS lowers IL-1ra and 
attenuates IL-8 and IL-6 [406]. In the present study G-CSF increased the LPS induced 
increase in IL-6 when LPS and G-CSF were administered at the same time. 
Furthermore, IL-6 synergises with G-CSF to promote tumour growth, and chemotaxis 
of bone marrow neutrophils [368]. This suggests that the protective effects of G-CSF 
during sepsis, may extend to skeletal muscle via a G-CSF/IL-6 cooperation, either 
promoting satellite cell activation. This remains to be determined using different models 
of inflammation such as sepsis, chronic disease and acute injury.  
 
Human primary skeletal muscle myotubes increase G-CSF in response to stretch 
induced damage in vitro [116]. However, since G-CSF is a known fibroblast growth 
factor [407] and fibroblasts contaminate primary satellite cell populations [385] the 
potential for G-CSF to be released by fibroblasts in primary cell cultures cannot be 
ruled out. Therefore, the site of G-CSF production may not be skeletal muscle during 
exercise induced damage. The increase in circulating G-CSF observed after 2 hours may 
be stimulated by an increase in pro-inflammatory cytokines during exercise-induced 
inflammation. Eccentric exercise [115, 313], high-intensity endurance exercise [390] 
and incremental exhaustive exercise [408] have significant muscle damage and 
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increased circulating cytokines including G-CSF. Therefore the increase in G-CSF post-
exercise may simply be a response to the increased systemic inflammation. 
Alternatively, endothelial cells, known to produce G-CSF [361], may release G-CSF 
directly into the circulation following muscle damage in order to mobilise bone marrow 
stem cells and granulocytes or induce chemotaxis of neutrophils. Thus an increase in G-
CSF would be observed in circulation but not necessarily within the muscle bed. 
However the precise site of G-CSF production following eccentric-damaging exercise 
remains unknown and muscle derived G-CSF cannot be ruled out due to the lack of G-
CSF mRNA data. For example, TNFα mRNA increases markedly in muscle during 
exercise  but only a small amount is secreted into the circulation [409], or it may simply 
be that the biopsies were not performed at time points sufficient to detect changes 
within the muscle.  
 
The current study is the first to show NAC does not affect elevated circulating G-CSF 
levels following eccentric-damaging exercise. Previous published data from this sample 
set show a reduced muscle recovery eight days after eccentric exercise following NAC 
supplementation [317]. This was associated with a blunted cytokine inflammatory 
response and a blunted response to redox-sensitive pathways in the NAC trial. NAC is 
known to inhibit G-CSF production of ROS and lead to reduced proliferation of BAF/3 
cells [314]. Therefore, in the current study, NAC supplementation may have blunted G-
CSF mediated ROS production. However this remains to be determined. 
 
In chapter 2 it was shown that the G-CSFR protein is down-regulated in skeletal muscle 
of mdx mice. Following eccentric-damaging exercise in humans the G-CSFR was not 
changed in the muscle tissue. Therefore the G-CSFR may be regulated in chronic 
diseased skeletal muscle, but not in healthy muscle or after acute damage.  
 
In conclusion, LPS stimulation increased G-CSF mRNA expression and G-CSF release 
in C2C12 myotubes. G-CSF treatment did not affect the basal levels of TNFα, IL-6 or 
MCP-1, however when G-CSF was treated with LPS, IL-6 was significantly elevated at 
the mRNA level which corresponded to an increase in IL-6 release. These findings 
suggest that G-CSF may cooperate with IL-6 during sepsis and potentially promote 
muscle regeneration by the mobilisation of satellite cells. Following eccentric-damaging 
exercise G-CSF was elevated in circulation at two hours post-exercise that did not 
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translate to an increase in the muscle. These results suggest that different models of 
inflammation may produce a different G-CSF response. The relevance of these findings 
remains to be determined.  
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CHAPTER SIX 
 
Summary of Major Findings and Future Directions 
 
6.1 Summary of Major Finding 
Granulocyte-colony stimulating factor (G-CSF) is widely known for its ability to 
stimulate the mobilisation of haematopoietic stem cells from the bone marrow [152, 
154], stimulate survival, proliferation, and differentiation of granulocytic precursors and 
activation of neutrophils [155, 156]. Signal transduction occurs via the G-CSFR and 
activation of intracellular signalling pathways including Akt, STAT3 and Erk1/2 [138, 
224, 318, 319]. In skeletal muscle, G-CSF improves muscle strength following injury in 
rodents [136]. The enhancement of muscle function is preceded by a significant increase 
in satellite cell proliferation, decreased apoptosis, increased regeneration, and higher 
muscle protein content. In other rodent models, G-CSF increases muscle repair 
following a local cardiotoxin injection [137] which is associated with an activation of 
Akt, STAT3 and Erk1/2 in C2C12 myoblasts in vitro [138]. G-CSF also increases motor 
function, muscle mass and muscle fibre size in ALS mice [223]. The signalling 
pathways known to propagate the effects of G-CSF in haematopoietic cells, neural 
tissue and cardiac myocytes are of vital importance for the growth and regeneration of 
skeletal muscle. The general aim of this PhD thesis was to determine the expression of 
G-CSF/G-CSFR in skeletal muscle, to understand the effects of G-CSF treatment 
directly on skeletal muscle using C2C12 cell cultures in vitro, and to provide important 
evidence supporting the use of G-CSF as a therapeutic agent in skeletal muscle. 
 
Chapter 2 showed for the first time that the G-CSFR was expressed in C2C12 and human 
primary myoblasts and myotubes, and in mature skeletal muscle. In diseased skeletal 
muscle from the mdx mice, a rodent model of DMD, G-CSF mRNA and protein was 
down-regulated. This was observed in the tibialis anterior (TA) muscle and importantly 
the diaphragm, which closely resembles the degeneration seen in skeletal muscle of 
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human DMD patients. However, the G-CSFR was differentially regulated in mdx 
muscle. G-CSFR mRNA expression was increased while protein expression was 
decreased in the TA and diaphragm. The role of altered G-CSF / G-CSFR levels in mdx 
mice needs to be further explored. Since the G-CSF treatment in ALS mice leads to an 
increased life span, and an increase in muscular function and muscle size, the same 
beneficial effects could be observed in the mdx mouse treated with G-CSF.   
 
In chapter 3 it was demonstrated that G-CSF treatment did not stimulate C2C12 myoblast 
proliferation. G-CSF treatment did not affect differentiation. This was analysed by the 
gene expression markers of differentiation markers myosin heavy chains (I, IIa, IIb and 
IIx) and the myogenic regulatory factors MyoD and myogenin which were not altered 
by G-CSF treatment during differentiation. High dose G-CSF treatment (100 ng/ml) 
increased G-CSFR mRNA at day 3 and day 4 during differentiation. This suggests that 
G-CSF may induce expression of its own receptor in a feed forward loop in skeletal 
muscle; the significance of which remains unknown. This study did demonstrate the 
need for rigorous controls during cell culture experiments. The increases in Akt, STAT3 
and Erk1/2 in C2C12 myoblasts has previously been attributed to the effects of G-CSF in 
C2C12 myoblasts [138]. Here it was shown that Akt, and Erk1/2 are responsive to media 
change effects, and G-CSF did not increase phosphorylation of these proteins above the 
vehicle control. Studies that do not employ rigorous controls need to be viewed with 
caution. This also leads to the possibility for a systematic review of many factors that 
claim to increase Akt and Erk1/2 in skeletal muscle, especially if the proper controls are 
not shown in publication. 
 
In chapter 4, G-CSF treatment did not influence protein synthesis under basal 
conditions. G-CSF treatment did however attenuate the DEX-induced reduction in 
protein synthesis at 4 and 40 ng/ml. At a higher dose of 100 ng/ml, G-CSF treatment 
exacerbated the DEX-induced reduction in protein synthesis. G-CSF treatment did not 
influence protein degradation under normal or DEX-induced catabolic conditions. This 
suggests that G-CSF treatment may protect muscle against a reduced protein synthesis 
under catabolic conditions. This response may lead to the improvement in muscle 
function and muscle mass observed with G-CSF treatment in injury and disease models. 
The molecular mechanisms by which G-CSF influenced protein synthesis under DEX-
induced catabolic conditions remain to be determined. Similarly it remains to be 
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determined if these results correlate to an increase in myotube diameter.  Similar to 
results obtained from chapter 3, G-CSF did not increase phosphorylation of Akt, 
STAT3 or Erk1/2 in C2C12 myotubes, rather the increases observed was attributed to the 
effects of changing media in C2C12 myotubes. The effect of G-CSF treatment on the 
phosphorylation of these proteins under DEX-induced catabolic conditions needs to be 
investigated. 
 
In chapter 5, it was shown for the first time that LPS treated myotubes increased G-CSF 
mRNA expression and the release of G-CSF into the culture media. As expected LPS 
treatment induced inflammatory cytokine mRNA expression of TNFα, IL-6 and MCP-1. 
The addition of G-CSF further increased the LPS induced increased in IL-6 above that 
of LPS alone. Cytokine release into the cell culture media followed the same pattern 
with LPS increasing MCP-a and IL-6, with G-CSF treatment further increasing the 
LPS-induced IL-6. TNFα was not detected in the media. In response to eccentric-
damaging exercise, G-CSF was elevated in circulation after 2 hours. This study showed 
that the increase in circulating G-CSF did not correspond to an increase in G-CSF in the 
skeletal muscle tissue. Circulating TNFα is increased in response to sepsis, but is rarely 
increased in response to exercise [404] and therefore G-CSF may have a similar 
regulation to TNFα. Understanding the role of G-CSF in the inflammatory response in 
muscle needs to be further investigated. This will provide further evidence to support G-
CSFs use as a therapeutic agent for improving skeletal muscle health during various 
conditions associated with muscle wasting.  
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6.2 Future directions 
6.2.1 The effects of G-CSF treatment on skeletal muscle function in mdx mice. 
Rationale 
The mdx mouse is characterised by constant periods of degeneration/regeneration 
resembling that of human DMD. In Chapter 2 it was shown that the mdx mouse has 
increased levels of circulating G-CSF however decreased G-CSF at the muscle tissue 
level. Furthermore the mdx mouse exhibits lower levels of G-CSFR protein in muscle 
tissue. The significance of this remains unknown, however, treatment with G-CSF in 
various models of injury and disease, leads to increased muscle function [223]. 
Therefore, it is plausible that G-CSF treatment may improve skeletal muscle 
regeneration in mdx mice and lead to improved motor function and quality of life.  
 
Aims 
To investigate the effects of eight weeks G-CSF treatment on muscle function in the 
mdx mouse.  
 
Key Methods 
Treatment of mdx mice should begin as early as possible since mdx mice show skeletal 
muscle degeneration and regeneration from an early age. G-CSF can be delivered by a 
subcutaneous osmotic mini-pump set at 30 μg/kg/day as previously described [223]. 
Outcome measures would include whole body strength, muscle fibre diameter and 
contractile function in vivo, as well as gene and protein expression analyses of potential 
G-CSF targets. The four limb hang test is a test used to measure whole-body strength 
and endurance in rodent models of neuromuscular disease. The test is relatively 
inexpensive and measures latency to fall. Muscle contractile function can be measured 
as described previously [410]. In brief, the tibialis anterior (TA) muscle is exposed by a 
single incision following anesthetisation. The TA muscle is stimulated by supramaximal 
(10 V) 0.2 ms square-wave pulses for 300 ms in duration, delivered via two wire 
electrodes adjacent to the femoral nerve. Muscle length (Lo) can be determined from 
maximal twitch force (Pt) and maximum tetanic force production (Po) recorded from the 
plateau of a full frequency-force curve. Optimum fibre length (Lf) can be determined by 
multiplying Lo by the TA Lf/Lo ratio of 0.6 [411]. An isometric contraction will be 
initiated and held for 100 ms to allow a plateau in maximal force. Muscle lengthening 
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occurs at a velocity of 2 Lf/s at progressively increasing magnitudes of stretch at 5, 10, 
20, 30 and 40 % of Lf with Po determined prior to each lengthening contraction. This 
protocol examines the functional deficits following successive lengthening contractions 
of increasing magnitude. Damaged myofibres can be identified by the infiltration of 
Evans blue dye (EBD) to determine differences in contraction-mediated damage. The 
inclusion of EBD allows the discrimination between an improved repair process or an 
improved susceptibility to contraction-induced damage [327].  Muscle fibre diameter 
can be measured by tissue sectioning microscopy, while gene and protein expression 
analyses can be performed using RT-PCR and western blotting respectively. 
 
 
6.2.2 The effects of serum starving and re-feeding on protein phosphorylation 
Rationale 
In Chapter 3 and 4 it was demonstrated that replenishing serum free DMEM in C2C12 
myoblasts and myotubes significantly increased major signalling pathways. Currently 
the literature is riddled with protocols that serum starve between three and 20 hours 
before performing experiments, and not all publication are clear in their methods or 
show the correct controls. Serum starving protocols may include, but are not limited to, 
serum free media, serum and protein free media and reduced serum usually 0.1-0.5% 
but as high as 2-5 % (discussed in [352]. It is commonly accepted that serum staving 
reduces the basal cell activity and shift all cells into the quiescent G0/G1 phase of the 
cell cycle.  However, Pirkmajer et al [352] showed that human primary myotubes and 
rat L6 myotubes respond differently to serum starvation. In particular Erk1/2 is elevated 
in human primary myotubes but reduced in L6 myotubes. Furthermore Pirkmajer et al 
[352] showed that phosphorylation of two intramuscular kinases, p70S6K and rp6K, are 
significantly elevated after 1-3 hours of serum staving and significantly decrease below 
baseline after 12-24 hours in human primary myotubes in vitro. These results suggest 
that consistencies between laboratories may not exist, producing potential misleading 
results within the literature. Therefore, assessing the effects of serum starving and 
developing standard protocols for the commonly used cell lines is vital for replicative 
results that can be translated into in vivo models. 
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Aim 
To compare the effects of serum starving and re-feeding on protein phosphorylation. 
 
Key methods 
Commonly used cell lines include C2C12, L6 and primary (human) cells. These cells can 
easily be grown in culture and treated as myoblasts or terminally differentiated to form 
myotube culture. It is common practice to serum starve cells prior to experimental 
treatments and therefore basal phosphorylation levels would be determined by western 
blotting following serum starving. Serum starving in DMEM at time intervals ranging 
from 3-20 hours is common and therefore these time intervals need to be assessed for 
the effects on phosphorylation. After determining the effects of serum staving, 
experimental treatments usually include time course assays to determine the effects on 
phosphorylation. In Chapter three and four re-feeding cells induced phosphorylation of 
Akt, STAT3 and Erk1/2 independently of G-CSF. Therefore using common reagents to 
determine the effects on phosphorylation has important consequences for designing 
experiments. Common treatment reagents include 10 % FBS, 2 % HS and serum free 
media with the addition of a carrier protein such as BSA.  
 
 
6.2.3 Determining the effects of G-CSF on DEX-induced C2C12 myotube diametre. 
Rationale 
In Chapter 4, G-CSF attenuated the dexamethasone (DEX)-induced reduction in protein 
synthesis at 4 and 40 ng/ml. At a higher dose of 100 ng/ml, G-CSF exacerbated the 
DEX-induced reduction in protein synthesis. Whether this relates to changes in myotube 
diameter under DEX-induced atrophy remains to be determined. Furthermore, G-CSF 
did not alter the phosphorylation of Akt, STAT3 and Erk1/2 under basal conditions. 
However, the effects of G-CSF treatment on the regulation of these signalling proteins 
under DEX-induces catabolic conditions remain to be determined. 
 
Aim 
To determine if G-CSF treatment during DEX-induced catabolism regulates C2C12 
myotube size and to determine the molecular mechanisms by which G-CSF influences 
protein synthesis under DEX-induced catabolism. 
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 Key methods 
Protein synthesis can be determined by measuring the incorporation of radio-labelled 
[3H]-tyrosine as described in chapter 4. To determine the radioactivity incorporated in 
cellular proteins, C2C12 myotubes treated for 24 hours with 10 μM DEX with and 
without G-CSF at a concentration of 4, 40 and 100 ng/ml. Myotube diameter can be 
determined by microscopy. RNA and protein can be extracted at various time points to 
assess the gene and protein expression levels by RT-PCR and western blotting, 
respectively, of protein associated with G-CSF/G-CSFR and protein synthesis. Gene 
protein targets include Akt, STAT3, Erk1/2 and the muscle specific atrophy genes 
Atrogin-1 and MuRF1. 
 
 
6.2.4 Determing the effects of G-CSF treatment on sepsis induced atrophy in C2C12 
myotubes in vitro and rodents in vivo. 
Rationale 
In chapter 5 it was demonstrated that G-CSF is elevated in C2C12 cell culture media 
following LPS stimulation. Furthermore G-CSF treatment in combination with LPS 
treatment resulted in an increased IL-6 response in C2C12 myotubes. Previously G-CSF 
treatment of rodents protects them against LPS induced toxicity, which is associated 
with a modulation of the inflammatory response. Following sepsis, skeletal muscle 
atrophy, reductions in force generating capacity and altered bioenergetics lead to poor 
health and a reduced quality of life through functional impairment and limitations in 
exercise capacity [398]. Therefore G-CSF may present itself as a safe and readily 
available treatment for sepsis induced atrophy and may improve quality of life 
following sepsis.  
 
Aim 
To determine if G-CSF protects against sepsis induced atrophy in C2C12 myotubes in 
vitro and in rodents in vivo.  
 
Key methods 
C2C12 myotubes treated with 1 μg/ml LPS ± 100 ng/ml G-CSF. Outcome measures 
include; protein synthesis and protein degradation which can be determined by 
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measuring the incorporation or release of radio-labelled [3H]-tyrosine into the myotubes 
as described in detail in chapter 4. Myotube diameter can be measured using 
microscopy. Gene can be determined by RT-PCR and protein determined by bioplex 
assay for cytokines in culture media and western blotting for intracellular proteins. 
Targets include inflammatory cytokines such as IL-6, TNFα and IL-1β, muscle specific 
atrophy genes (Atrogin-1 and MuRF1), and intracellular signalling proteins Akt, 
STAT3 and Erk1/2.  
 
Rodent models of sepsis-induced atrophy have previously been established, which 
mimic the long-lasting muscle wasting observed in humans [412]. In brief, male 
Sprague-Dawley rats weighing approximately 250 g injected with 0.5 ml (1.3 x 109/ml)  
live E. coli serotype O153:K-:H- strain administered intravenously through the lateral 
tail vein mimics the muscle atrophy observed in infected patients. This model does not 
produce a high mortality rate or a reduced atrophy observed with injecting non live 
bacteria via intra peritoneal (i.p) injection (discussed in [412]). 250 μg/kg/day of G-CSF 
treatment protects rodents against LPS induced toxicity [400]. However i.v. injections 
of live E. coli produce a lower mortality rate and therefore a lower 50 ug/kg/day G-CSF 
would be tested. G-CSF would be administered following E. coli for clinical 
significance and would continue for 5 days. Food intake could be either limited or 
monitored during the experimental period. Outcome measures include changes in body 
mass, total muscle weight and total protein content of the gastrocnemius as previously 
described [412]. Intramuscular gene and protein analysis would be analysed using RT-
PCR and western blotting techniques and would include the muscle specific atrophy 
genes (Atrogin-1 and MuRF1), and intracellular signalling proteins associated with G-
CSF signalling; Akt, STAT3 and Erk1/2. Other outcome measures include mean rectal 
temperature, circulating leukocyte counts, the number of bacteria found in various 
tissues including the blood, liver, kidneys and spleen, and cytokine levels in circulation 
and muscle as described in chapter 5. Cytokine targets include G-CSF, IL-6, TNFα and 
IL-1β.  
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Appendices  
 
Table S1. G-CSFR mRNA Sequencing Files.  
BAF/3 Forward primer 
>MQ-BAF3.mGCSFR-F sequence 
exported from MQ-BAF3.mGCSFR-
F_D12_008.ab1 
NNNNNNNNGNCTTACCCTGAGGNNCCTAGATCCNTCTGACTTA
AACATTTTCCTGGGCATACTTTGCTTAGTACTCTTGTCCACTAC
CTGTGTAGTGACCTGGCTCTGCTGCAAACGCAGAGGAAAGACT
TCCTTCTGGTCAGATGTGCCAGACCCAGCCCACAGTAGCCTGA
GCTCCTGGTTGCCCACCATCATGACAGAGGAAACCTTCCAGTT
ACCCAGCTTCTGGGACTCCAGCGTGAA 
BAF/3 Reverse primer 
>MQ-BAF3.mGCSFR-R sequence 
exported from MQ-BAF3.mGCSFR-
R_E12_010.ab1 
NNNNNNNNNNNNNGTCNTGATGGTGNNNNNCAGGAGCTCAG
GCTACTGTGGGCTGGGTCTGGCACATCTGACCAGAAGGAAGTC
TTTCCTCTGCGTTTGCAGCAGAGCCAGGTCACTACACAGGTAG
TGGACAAGAGTACTAAGCAAAGTATGCCCAGGAAAATGTTTA
AGTCAGATGGATCTAGGGTCCTCAGGGTAAGGCCTGTACTATT
GGTGGACCCTGCTCGACTGGTGGCCATGAAA 
C2C12 Myoblasts Forward Primer 
>MQ-C2C12.mGCSFR-F sequence 
exported from MQ-
C2C12.mGCSFR-F_B12_004.ab1 
NNNNNNNNNNTTANCCTGAGGANCCTAGATCCNTCTGACATA
AACATTTTCCTGGGCATACTTTGCTTAGTACTCTTGTCCATTAC
CTGTGTAATCGCCTGGCTCTGCTACAAGCACAGAGGAAAGACT
TTCTTCTGGTCAAATGTGCCAGACCCAGCCCACAGTAGCCTGA
GCTCCTGGTTCCCAACATCATGACAGAGGAAACCTTCCAGTTA
CCCAGCTTCTGGGACTCCAGCGTGAA 
C2C12 Myoblasts Reverse Primer 
>MQ-C2C12.mGCSFR-R sequence 
exported from MQ-
C2C12.mGCSFR-R_C12_009.ab1 
NNNNNNNNNNNNNNGNCNTGATGTTGGGACCNGGAGCTCAGG
CTACTGTGGGCTGGGTCTGGCACATTTGACCAGAAGAAAGTCT
TTCCTCTGTGCTTGTAGCAGAGCCAGGCGATTACACAGGTAAT
GGACAAGAGTACTAAGCAAAGTATGCCCAGGAAAATGTTTAT
GTCAGATGGATCTAGGGTCCTCAGGGTAAGACCTGTACTGTTG
GTGGACCCTGCTCGACTGGTGGCCANNNNN 
C2C12 Myotube Forward Primer 
>MQ-C2C12.mGCSFR-F sequence 
exported from MQ-
C2C12.mGCSFR-R_A12_012.ab1 
NNNNNNNNGNCTTACCCTGAGGNNCCTAGATCCNTCTGACTTA
AACATTTTCCTGGGCATACTTTGCTTAGTACTCTTGTCCATTAC
CTGTGTAATCGCCTGGCTCTGCTACAAGCACAGAGGAAAGACT
TTCTTCTGGTCAAATGTGCCAGACCCAGCCCACAGTAGCCTGA
GCTCCTGGTTGCCCACCATCATGACAGAGGAAACCTTCCAGTT
ACCCAGCTTCTGGGACTCCAGCGTGAA 
C2C12 Myotube Forward Primer 
>MQ-C2C12.mGCSFR-R sequence 
exported from MQ-
C2C12.mGCSFR-R_G12_002.ab1 
NNNNNNNNNNNNNNGNCNTGATGTTGGGACCNGGAGCTCAGG
CTACTGTGGGCTGGGTCTGGCACATTTGACCAGAAGAAAGTCT
TTCCTCTGTGCTTGTAGCAGAGCCAGGCGATTACACAGGTAAT
GGACAAGAGTACTAAGCAAAGTATGCCCAGGAAAATGTTTAA
GTCAGATGGATCTAGGGTCCTCAGGGTAAGGCCTGTACTATTG
GTGGACCCTGCTCGACTGGTGGCCATGNNN 
 
 

